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Extensive long-range linkage disequilibrium within the MHC region, 
commonly termed as conserved extended haplotypes (CEHs), are known to 
occur at relatively high frequency in the general populations. CEHs have been 
of long interest not just because of their unique genomic traits but also 
because they are reported to be associated with several diseases. However 
due to the inherent heterogeneity of the MHC region and the limitation of the 
technologies, thus far, the handful of studies on the genomic structure of 
MHC CEHs have been restricted to the European population. This lack of 
comparative MHC CEH sequence information in other ethnic groups hampers 
the efforts to elucidate the structure and genomic organization of CEHs. 
In this study, the recombination patterns across the MHC region in 
three independent populations were examined. This analysis revealed 
population-specific recombination sites and these sites are seldom shared 
among populations, underlining the importance of recombination on haplotype 
diversity. Furthermore, from the SNPs analysis, I also uncovered two HLA 
haplotypes in the Singaporean Chinese population (A*33:03-B*58:01-
DR*03:01 and A*02:07-B*46:01-DR*09:01) with no or minimal recombination 
across the MHC region, suggesting CEH properties in these haplotypes. 
To have an in-depth genomic architecture on above two Singapore 
Chinese HLA haplotypes, multiple HLA homozygous B-LCLs were selected 
and subjected to whole genome sequencing.  The analysis of this data 
revealed two significant findings. Firstly, extensive sequence conservation 
spanning a region of at least 3Mb of the MHC genomic region was found 
among the individuals carrying identical HLA haplotype. In addition, the intra-
haplotypic variations within these CEHs were found to be exceptionally low 
comprising of approximate 0.008% of the MHC region. Novel single 
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nucleotide variation (SNV) not reported in other databases were found in 
77/293 (26%) of A*33:03-B*58:01-DR*03:01 CEH and 50/238 (21%) of the 
A*02:07-B*46:01-DR*09:01 CEH. More importantly, SNVs found within the 
A*02:07-B*46:01-DR*09:01 CEH were associated with the expression of 
ZFP57, a transcription factor involved in DNA methylation maintenance; 
suggesting functional role in some of these polymorphic sites. The second 
major finding is that extreme sequence conservation extending up to 160kb at 
the HLA-DR region was found between the A*33:03-B*58:01-DR*03:01 
haplotype and the European A1-B8-DR3 haplotype; implying individuals 
carrying these two haplotypes shared a common ancestor. 
Next, the MHC transcription landscape of the Singaporean Chinese 
CEHs was also elucidated through RNA-sequencing. Interestingly, 
differences in gene expression between haplotypes affecting 26 genes were 
observed; this implies the influence of underlying MHC haplotypic structure on 
the transcription activity in the MHC region. Collectively, a comprehensive 
sequence and transcription description representative of the A*33:03-
B*58:01-DR*03:01 and A*02:07-B*46:01-DR*09:01 haplotype was provided 
and I had showed that haplotype-specific sequence variations mediate the 
level of gene expression in the MHC. The availability of these alternate Asian 
MHC sequences would complement the eight European MHC haplotype 
sequenced by the MHC Haplotype Project and provides a framework to study 























1.1 Overview of the MHC 
The human major histocompatibility complex (MHC) was first identified 
more than 50 years ago by Jean Dausset, Jon van Rood and Rose Payne [1] 
and because the MHC molecules were first detected on the surface of the 
human leukocytes, the human MHC was later also known as the human 
leukocyte antigen (HLA) complex. In the beginning, it was studied due to its 
role on the donor-patient compatibility following tissue graft and organ 
transplantation [2, 3], it was later realized that the MHC is critical in adaptive 
and innate immunity.  
Decades of research has progressively established a remarkable genomic 
region on chromosome position 6p21.3 comprising of the HLA genes and the 
associative genes. This region is the most gene-dense region in the human 
genome holding more than 240 annotated genes, of which more than 60 have 
known or potential immune-related function [4, 5]. Furthermore, the extreme 
genetic variation within this region has a pivotal role in the disease 
susceptibility and indeed this four mega-base region has been reported to be 
associated with more than 100 diseases, including cancers, autoimmune 
diseases, infectious disease susceptibilities, neurodegenerative, 
cardiovascular, and metabolic disorders [6, 7]. In addition, the MHC region 
possesses unique genomic features offering an excellent model to study 
demographic events as well as to assess hypotheses pertaining to the 
dynamics of evolution [8, 9]. For these reasons, the MHC genomic 
architecture, diversity, gene expression and genetic interaction pathways 





1.2 MHC Gene Map and Organization 
The human MHC region of approximate 4.6 Mb on the short arm of 
chromosome 6 (chr6:29.50 – 33.10Mb) is broadly categorized into three 
major gene clusters – classical HLA class I, class II and class III (Figure 1.1) 
[4]. The HLA class I gene cluster spanning about 1.9Mb with a total of 26 
coding and pseudogene loci; comprises of the classical class I genes (HLA-A, 
-B and -C), the non-classical class I genes (HLA-F, -G and -E) and the class I 
resembling genes (MICA and MICB). The HLA class II gene cluster of 
approximate 0.9Mb in length with a total of 24 coding and 15 pseudogene 
loci;  comprises of the classical class II genes (HLA-DP, -DQ and -DR) and 
the non-classical class II genes (HLA-DM and –DO). Each of these class II 
genes are expressed as hetero-dimers consisting of the α and β chain. The 
class III region with a relatively short physical length of 0.7Mb, harbors more 
genes than the other two clusters and is the most gene-dense region in the 
human genome. Although this region does not encode any of the HLA genes, 
it holds several sub-gene clusters that are crucial to the immune system such 
as those involved in inflammation and immune regulation (Figure 1.2). There 
are also other major gene clusters that border the MHC region and 
collectively are known as the extended MHC region covering 7.6Mb [4]. 
These gene clusters include the histone cluster (chr6:25.72 – 27.81Mb), the 
zinc finger cluster (chr6:28.04 – 28.56Mb), the olfactory receptor cluster 
(chr6:29.00 – 29.56Mb) and the extended class II sub-region containing the 









Figure 1.1 The human MHC region expressed genes. This region is 
divided into three major gene clusters: Classical HLA class I (blue), HLA class 
















Figure 1.2 A simplified gene map of MHC showing the immune related 











1.3 MHC Diversity 
 
1.3.1 HLA Molecules Diversity 
Extreme sequence polymorphism is the hallmark of the HLA class I and 
class II genes. Since their initial discovery, hundreds of different variants of 
the genes or alleles has emerged and as of 2013, there are 9946 distinct HLA 
class I and class II alleles and amazingly new alleles are still being identified 
yearly, demonstrating the extreme variation found in these loci. With 3086 
alleles, the HLA-B gene is the most polymorphic gene in the human genome 
followed by the HLA-A gene with 2432 alleles (Figure 1.3) [11].  For HLA 
class I genes, the majority of the nucleotide differences are located in the 
exon 2 and 3; and in exon 2 of the HLA class II genes with the exception of 
HLA-DRA gene. These exons are responsible for the coding of the antigenic 
peptides binding domain, hence non-synonymous nucleotide changes leading 
to amino acid modification in this domain alter the HLA molecule antigenic 
peptides binding capability [12]. Most of the HLA genes nucleotide variations 
are found in the exonic region as described above; this is in contradictory to 
other functional genes in the human genome where most variants are located 
in the introns [13]. In addition, these variations are effect of germline 














Figure 1.3 Number of alleles identified for class I, class II and non-HLA 











The ever-increasing number of new HLA alleles being discovered 
necessitates a standardized nomenclature for the naming of the alleles. The 
WHO Nomenclature Committee for Factors of the HLA system established a 
standard HLA allele specification where each HLA allele is denoted by its 
gene name and an asterisk; this is followed by a distinct identification of four 
sets of numbers delimited by colons. The first set of number defines the 
allotype; alleles that differ by nucleotide changes that alter the amino acid in 
the encoded protein are discriminated by the second set of numbers while 
alleles differ by synonymous nucleotide changes in the coding region are 
differentiated by the third set of numbers. The last set of numbers defined the 
changes in the non-coding region.  
 
1.3.2 Genetic Variation across the MHC Region 
Besides the need to characterize of the HLA gene variation, information 
on the sequence variability in the MHC region as a whole is equally important; 
and in particular is relevant in the context of MHC disease association as well 
as the genealogical relationship between individuals or ethnic groups. This 
endeavor was first taken upon by the MHC Haplotype Project which aims to 
define the common sequence differences within the MHC region for MHC 
disease susceptibility studies [14-16]. Using bacterial artificial chromosome 
cloning (BACs) and shotgun sequencing, these studies sequenced eight 
common MHC haplotypes of European ancestry established from HLA-
homozygous consanguineous B-lymphoblastoid cell lines and in the process 
characterized more than 37,000 single nucleotide variants and 7,000 short 
insertions/deletions. This extensive catalogue of variations enabled the 
establishment of linkage disequilibrium maps that facilitated the localization of 
susceptibility loci pertaining to multiple sclerosis and type I diabetes [17, 18]. 
8 
 
Subsequently, independent groups employed a variety of approaches such as 
targeted amplicons-based methods and a combination of targeted sequence 
enrichment and next-generation sequencing to interrogate the distribution of 
variation across the MHC region [19-21]. Despite these impressive efforts, the 
MHC sequences described to date are mostly reflective of the European 
population; thus more efforts are still needed to acquire an adequately sized 
reference MHC sequences for other ethnic groups. 
 
1.3.3 MHC Hyper-variable Regions 
Several genomic regions within the MHC have undergone repeated 
segmental duplications resulting in structural copy number variation; most 
notably the HLA-DR region and in the class III region that holds the 
complement component C4 gene. The HLA-DR hyper-variable region 
contains a variable number of functional and pseudo HLA-DRB genes that 
result in different alternative arrangements of the HLA-DRB genes 
(haplogroups) [22]. To date, five such haplogroups have been identified; each 
possessing a specific arrangement of the HLA-DRB genes (Figure 1.4). The 
boundaries of all the haplogroups are characterized by the HLA-DRA gene at 
the telomeric end and the HLA-DRB1 gene at the centromeric end and all the 

















Figure 1.4 Five major HLA-DR haplogroups structure. Green boxes 
denote functional genes and blue boxes denote pseudogenes. This figure is 










Additional HLA-DR genes are positioned between the HLA-DRB9 and HLA-
DRB1; the arrangement, the number and the type of HLA-DRB genes in this 
segment are dependent on the haplogroups. Interestingly, through in-vitro 
and in-vivo studies, differential transcripts expression was observed between 
haplogroups in resting peripheral B cells and within the same haplogroup the 
different DRB genes had equivalent transcripts abundance [24, 25].  
However, the functional effect of having additional or lesser HLA-DRB 
gene(s) remains unclear. 
The other region with sophisticated segmental duplication is in the class 
III region is called the RCCX module, named for its gene content, comprises 
of the serine/threonine Kinase 19 (RP1), the complement component (C4), 
the cytochrome P450 (CYP21) and the tenascin X (TNX) gene map to the 
chromosome in a chronological manner.   Within the module, different 
variants of these genes can be presented; RP1 or RP2 (pseudogene), C4A or 
C4B, CYP21A or CYP21A1P (pseudogene) and TXNA (pseudogene) or 
TNXB [26]. The C4A and C4B can also exist in either long (C4L) or short 
(C4S) version which is differed by the presence or absence of the HERV-K 
endogenous retrovirus in the intron 9. Intriguingly, added to the complexity, a 
single chromosome can hold one to four copies of the RCCX module (Figure 
1.5) [26]. Population studies had revealed high frequency of heterozgosity in 
the RCCX module configuration [27] and this can drive unequal crossovers 
during meiosis resulting in the acquisition of deleterious mutations [28-30]. In 
fact, there is a strong association of the RCCX copy number variation with 
human systemic lupus erythematosus (SLE) where low RCCX copy number 












Figure 1.5 Organization of human RCCX modular variation. The C4 gene 
can either exist as C4A or C4B with either the presence (C4L) or absence 
(C4S) of the endogenous retrovirus HERV-K. Pseudogenes are presented in 












1.4 Haplotypes, Linkage Disequilibrium and Recombination 
High linkage disequilibrium (LD) is a distinctive feature of the MHC region. 
Indeed, inheritance of non-random association of HLA alleles at numerous 
loci was observed within the MHC [33, 34] and this leads to the concept of 
“polymorphic frozen blocks” where combination of identical block sequences 
are shared among individuals in populations commonly termed as haplotypes 
[35]. Strong LD is noted between HLA-A and HLA-B; HLA-B and HLA-C as 
well as HLA-DRB1 and HLA-DQB1 evidenced by the extremely low 
recombination rates between these loci [36].  In addition, there exists long 
conserved sequences across multiple HLA alleles spanning over several 
mega-bases that are observed at relatively high frequency within populations 
and is referred as “Conserved Extended Haplotypes” (CEH) or “Ancestral 
Haplotypes” [37]. These CEHs appear to account for 33% of the total 
European MHC haplotypes and majority of the population possess at least 
one of these CEHs or their recombinants [37-39].  Despite the proposal of 
numerous theories, the mechanism behind the CEHs formation and age of 
their divergence from a common ancestor remain ambiguous [10, 13]. 
Interestingly, many of these CEHs are reported to be associated to multiple 
complex diseases. This is best exemplified by the A1-B8-DR3 CEH found in 
the Northern European population which is remarkably associated with 
several diseases such as for type 1 diabetes, systemic lupus erythematosus, 






Recombination within the MHC region plays an important role in 
maintaining the haplotype diversity in populations where the reshuffling of 
genomic segments leads to the generation of new haplotypes [43-45]. In the 
earlier years, the analysis of recombination activity in the human was 
restricted to pedigree studies [46]. Later, with the maturation of the sperm 
typing technique, enables screening of thousands of single sperms and this 
approach generated a high resolution MHC recombination map that 
definitively identified six recombination sites within the MHC [45, 47, 48]. 
However, due to the technical difficulties, such studies are limited in scale and 
are only male-specific. The advent of high density SNP genotyping assay 
allows the characterization of LD patterns which can be used to infer 
recombination events across the MHC region. Systematic analysis of the SNP 
genotype data from the European population revealed non uniform 
recombination and LD patterns across the MHC where regions of high LD are 
flanked by spikes in recombination activities [49-51]. In addition, these studies 
are able to confirm the recombination sites derived from the sperm typing 
experiments as well as detect novel recombination sites. A subsequent study 
went on to characterize the LD patterns in multiple populations and 
demonstrated that the MHC haplotypic structure is dependent on the 
underlying HLA allelic combinations [52]. On the whole, the current 
knowledge of MHC recombination pattern is derived from the LD structure 
analysis of admixed-population data and did not account for the background 
HLA allelic; hence recombination site in particular those specific to a single 
ethnic or population group could have been missed out. The availability of a 
comprehensive population-specific recombination and LD map can facilitate 
the mapping and localization of genetic segment associated with diseases in 
the MHC [53, 54]. 
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1.5 Immune Function 
The MHC molecules are essential components for the human immune 
surveillance. Both the MHC Class I and Class II molecules interact with 
antigenic peptides and present the peptides on the cell surface to CD8+ and 
CD4+ T cells respectively to initiate immune responses.  The MHC class I 
molecules are expressed in all nucleated cells and present intracellular 
peptides of length 8-15 amino acids that are processed by proteasomes [55] 
(Figure 1.6). Furthermore, the presented MHC class I molecule-peptides 
complexes serve as ligands for the inhibitory killer cell immunologobulin-like 
receptors (KIRs) on natural killers (NK) cells and KIRs interactions with the 
MHC class I complexes inhibit the activation of NK cells. Reduction in the 
MHC class I expression in malfunction cells such as viral infected and tumor 
cells result in NK cells activation and elimination of the malfunction cells [56].  
Unlike the MHC class I molecules which are expressed in most cells, the 
MHC class II molecules are predominantly expressed in professional antigen-
presenting cells such as the dendritic cells and marcophages.  MHC class II 
molecules bind to antigenic peptides generated from extracellular proteins 
processed by the endocytic pathway [55]. Cross-presentation is also possible 
where peptides derived from the endocytic pathway bind to the MHC class I 
molecules and are presented to CD8+ T cells [57]. It is well established that 
the MHC molecules can bind to a large repertoires of antigenic peptides 









Figure 1.6 Immune functions of genes within the MHC region. MHC class 
I and II genes as well as non-HLA genes such as TAP1, TAP2, PSMMB8/9, 
tapasin play key roles in the antigen progressing and presentation pathway. 
The MHC region also contains genes such the TNF and MICA/B that have 
crucial roles in the human immunity system. This figure is adapted from 




 Extreme polymorphism in these molecules especially in the peptide-binding 
groove ensure the broadest range of antigenic peptides to be recognized and 
hence protection against a variety of pathogens. It is interesting to note that 
the MHC alleles have overlapping peptide-binding specificities and this 
peptide-binding promiscuity is observed in alleles within each HLA gene as 
well as across alleles from different HLA genes [59-61]. 
Besides the MHC molecules, the MHC region also harbors many genes 
with important immune functions (Figure 1.6). Most notably is the set of genes 
that encode proteins involved in the antigen processing pathway. The TAP1 
and TAP2 genes located in the class II region encode the transporter protein 
responsible for the delivery of the peptides into the endoplasmic reticurlum 
(ER) where the peptides are loaded on the MHC class I molecules and the 
TAPBP encodes the tapasin protein which is a dedicated MHC class I 
molecules chaperone involved in the peptide loading process in the ER [62]. 
In additional, the PSMB9 and PSMB8 encode the components of the 
proteasomes responsible for the fragmentation of cytosolic and nuclear 
proteins into short length peptides. It appears that the clustering of these 
genes related by their functions facilitated the gene expression and genetic 
exchange between the linkage genes [10]. Another important set of genes is 
the stress response genes MICA and MICB. These highly polymorphic genes 
encode molecules that serve as ligands for NKG2D which is an activating 
receptor expressed in NK cells [63]. In events of stress, infection or during 
tumorgenesis, MICA/B are over expressed on the surface of many cell types 
and the binding of these molecules to NKG2D activate the NK cells leading to 
the cytoxic response to the MICA/B expressing cells [64]. There is also a 
cluster of genes in the class III region that are involved in inflammation in 
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particular the tumor necrosis factor (TNF) encoding gene. TNF is a 
proinflammatory cytokine involves in cellular and inflammatory reaction and it 
was reported that polymorphism in the TNF regulatory region influence the 
amount of TNF production which could affect inflammatory responses [65, 
66]. 
 
1.6 Maintenance of Genetic Diversity in the MHC 
The mechanisms that drive and maintain the extreme genetic polymorphism 
at the MHC loci have been an interesting field of study on its own especially in 
evolutionary biology. Due to the MHC’s importance role in pathogen 
resistance, it has been long suggested that pathogen mediated balancing 
selection is the driving factor behind the maintenance of MHC diversity [67, 
68]. Three main mechanisms of pathogen mediated balancing selection, 
supported by strong theoretical evidence, have been hypothesized; 
heterozygote advantage through over-dominance model [67], negative 
frequency-dependence [69] and fluctuating selection [70].  
The heterozygote advantage through over-dominance states that 
individuals who are heterozygous at the MHC loci have a boarder range of 
recognized non-self antigenic peptides and as the result has a greater fitness 
against pathogens than individuals who are homozyguous at the MHC loci. 
Hence to improve pathogen resistance, MHC diversity is maintained in the 
population [71]. Evidence through empirical means has demonstrated that 
optimize rather than maximize amount of MHC diversity provides the greatest 
fitness advantage [72, 73]. It was put forward that having overly high amount 
of MHC diversity might result in the restriction of T-cell variation because of 
the removal of T-cells that response to MHC molecule self-peptide complex 
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[74]. The second likely MHC diversity driving mechanism is called the 
negative frequency-dependence whereby pathogens undergo selection to 
evade the recognition of the most common MHC alleles in the population and 
hence these common alleles are selected against and decrease in frequency 
in the population; while the frequency of novel alleles that provide improved 
resistance to the pathogen increases [75]. As the old alleles become rare, the 
pathogens resistance against them is diminished and causes their frequency 
to rise again. This recurring co-evolutionary competition results in the 
frequency fluctuation of the pathogens and the MHC alleles; in the process 
sustaining the MHC diversity in the populations [69]. The third proposed 
mechanism is the fluctuating selection whereby the existence of different 
pathogen strains in different populations results in the selection of different 
subsets of MHC alleles across different time and/or space [70]. As opposed to 
the negative frequency-dependence, selection imposed by fluctuating 
selection is directional rather than cyclical and pathogen evolution is 
independent of the MHC selection [9].  Determining which mechanism as the 
dominant factor is difficult; it is more likely that these mechanisms operate in 
conjunction with each another in the maintenance of the MHC diversity [76]. 
Besides pathogen mediated balancing selection, HLA intra-locus and inter-
locus gene conversion via homologous recombination of short DNA fragment 
can contribute to the generation of the MHC diversity especially in the 
peptide-binding groove [77]. For instance, the HLA-B*46:01 allele is product 
of the inter-locus gene conversion of HLA-B*15:01 and HLA-C*01:02 allele 
[78]. Some of these newly generated alleles will establish in the population 
through genetic drift and selection.  
The above models discussed are all established to understand the 
evolutionary processes that give rise to the observed polymorphisms in a 
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single MHC locus and hence these models are unable to provide satisfactory 
explanation for HLA haplotype (multiple genes) diversity and the LD that 
creates this genetic fixation. To account for these, an alternate theory named 
associative balancing complex is proposed [79]. This theory states that 
deleterious nucleotide changes are accumulated in large genetic segments 
fixed by high LD (haploblocks) via the Muller’s ratchet mechanism. Due to the 
high gene density in these segments, the deleterious nucleotide changes are 
often expressed as heterozygotes; as result purifying selection is ineffective in 
clearing these deleterious nucleotide changes and recombination is 
suppressed. Thus, the deleterious nucleotide changes are fixed into the 
haploblocks and propagate through generations. 
 
1.7 Disease Associations in the MHC 
The MHC region is linked to many diseases including infectious, 
inflammation-related and autoimmune conditions. In fact, no other region in 
the human genome is associated with more diseases than the MHC region 
[40]. Many of the early disease associations in the MHC were identified 
through hypothesis-based candidate gene approach by studying the HLA 
genes [80]. The tight association of genes in the MHC region allows the HLA 
genes to be used as the focal point to detect disease association; however 
isolating the causative genes are challenging. The availability of high-
throughput single nucleotide polymorphisms (SNPs) enables the 
implementation of unbiased and hypothesis-free large-scale genome-wide 
association studies (GWAS). These GWAS studies detected the association 
of common genetic variants within the MHC region with a range of diseases 
and; to date, more than 100 MHC linked diseases have been identified and 
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replicated in independent works (Figure 1.7). It is noted a number of these 
diseases such multiple sclerosis [81], nasopharyngeal carcinoma [82] and 
rheumatoid arthritis [83] are implicated by multiple genetic variants across the 
MHC region, suggesting multiple MHC genes may contribute to the disease 
condition. This multiple gene effects on diseases is not surprising given that 
genes within the MHC region are functionally involved in the similar pathway 
or system.  
The prominent role of the MHC region in disease is without doubt; 
however establishing a direct genetic link between a MHC gene and a 
disease is problematic and is often confounded by at least three factors: the 
effects of multiple genes, high gene density and the extreme LD in the MHC 
region [12]. As the result, these prevent the unambiguous detection of 
disease causative variants in the MHC region The inability to identify disease-
causing variants hampers the efforts to understand how these variants or 
genes within the MHC region influence the underlying mechanism that leads 
to the disease progression and development. 
 









                                                                                                                            
 
Figure 1.7 Disease-associated SNPs in the MHC region identified through 
genome-wide association studies. Each blue circle denotes the position of the 
SNP and its corresponding P-value. The SNP-disease associations listed are 
limited to those with P-values < 1x10-5. The data was extracted from the 





1.7.1 Infectious Diseases 
Given that host response against viral infection depends heavily on HLA-
restricted T-cell response, it is not surprising that most infectious diseases are 
associated with the HLA loci. Indeed, it was found that resistance to viral 
infection is linked to the HLA loci polymorphisms; most notably in HIV 
whereby escape variants of HIV-1 generates peptides that avoid T-cell 
recognition [85, 86]. For instance, the association of HLA-B*35 subtypes are 
linked to rapid HIV disease development and it appears that HLA-B*35-
restricted HIV -1 variants evade CD8+ T cell recognition by affecting peptide 
binding as well as T-cell receptor interaction with the HLA complex [87]. Other 
than the influence the HLA loci polymorphism on viral infection, a variant at 
the 3’ end of HLA-C was found to be associated to low HIV-1 viral load. It was 
revealed that the change of nucleotide at this position allows the binding of a 
miRNA and causes the down-regulation of HLA-C expression [88]. 
Heterogeneity at the HLA loci can also influence the clearing of viral infection 
and mortality. Individuals who are heterozygous at the HLA alleles have 
advantage over those who are HLA homozygous in the outcome of infection 
which in principal HLA heterozygosity increases the viral peptide repertoire 
pool and response to infection [89, 90]. In hepatitis B viral infection, 
heterogeneity across the HLA class II loci was demonstrated to have more 
favorable disease outcome [91]. 
 
1.7.2 Autoimmune Diseases 
The MHC region is the major genetic risk contributor to most if not all 
autoimmune diseases [92-94]. GWAS studies have consistently revealed the 
associations of genetic variants within the MHC region in particular the HLA 
23 
 
loci with autoimmune diseases and often these associations present the 
highest statistical signal and have considerably greater effect sizes than other 
part of the human genome. Despite the abundance of genetic studies linking 
the MHC region to autoimmune diseases, the underlying mechanism behind 
the MHC association still remains ambiguous. It has been long proposed that 
the interaction of T cell receptor with a self-peptide MHC complex could 
trigger an autoimmune response; although there is little or no evidence to 
prove the identity of these self-peptides [7].  
Recently, large-scale studies with adequate statistical power revealed 
multiple independent associations within the MHC region in 7 prominent 
autoimmune diseases [95, 96]. These studies demonstrated that disease 
associations were not just restricted to the HLA class I and class II genes; but 
also possible independent contributions from non-HLA genes (Figure 1.8). 
For example, in systemic lupus erythematosus, in addition to the HLA genes, 
associations were found in TNF, C4 and Notch4 genes.  Furthermore, these 
studies were able to show the primary HLA alleles driving the association; 
HLA-DRB1*15:01/HLA-DRB1*03:01 in systemic lupus erythematosus and 
HLA-B*44:02/HLA-DRB1*15:01 in multiple sclerosis. Despite these 
progresses, the dissection of individual genes contribution for psoriasis 
remains elusive. Psoriasis was associated with a genomic segment 
containing HLA-C and it was reported that both the HLA-C*06:02 and the 
nearby C6orf10 were linked to the disease susceptibility [97, 98]. However 
due to the high gene density and LD in this region, the actual contribution of 










Figure 1.8 Location of loci linked to 7 autoimmune diseases across the 
MHC region. Primary signals associated with the disease are indicated in red 
while secondary signals are indicated as blue. Secondary signals are referred 
as independent association with P-value <0.001 that demonstrated pair-wise 
correlation <0.2 with the surrounding SNP loci after logistic regression 
analysis for the primary associations. This figure is adapted and modified 







1.7.3 Other Conditions 
Besides infectious and autoimmune diseases, other conditions such as 
cancers and drug-induced allergy conditions are implicated by genetic 
elements within the MHC region. Tumors development and progression are 
often linked to aberrations in genes involved antigen processing and 
presentation pathway [99]. It has been described that tumors in colorectal 
carcinoma, melamoma and cervical carcinoma alter the surface expression of 
HLA class I molecules to evade T-cells recognition [100-102]. In addition, 
defects in TAP either at the transcript or protein level resulting to the 
disruption of antigen processing pathway is found in several tumors [100, 
103, 104].   
Interestingly, several drug-induced acute reactions are associated with 
specific HLA alleles. Notably is the association of HLA-B*57:01 with sensitivity 
induced by abacavir as well as HLA-B*15:02 with Stevens-Johnson syndrome 
induced by carbamazepine [105, 106]. Recent developments have provided 
insights on the underlying mechanism that leads to the observed association. 
It was found that the abacavir drug molecule bound non-covalently into the 
peptide–binding groove of the HLA-B*57:01 molecule and changed its peptide 
binding specificity. This caused the binding of a novel set of self-peptides in 
the presence of abacavir to HLA-B*57:01 and the resulting to T cell reactivity 
[107]. Similarity, the binding of carbamazepine to HLA-B*15:02 altered its 







The interrelated functions of the genes within the MHC region have 
brought about extensive active epistasis and this genetic interaction between 
multiple genes plays a significant role in shaping the patterns of LD. The 
knowledge of epistatic interaction between multiple genes is an important 
component for successful disease association studies. The DRB region, 
involving specific alleles of two genes in complete LD – HLA-DRB1*15:01 and 
HLA-DRB5*01:01, is reported to be a major candidate for multiple sclerosis 
susceptibility [109]. A subsequent study, demonstrated the presence of 
functional epistasis that lead to the complete LD observed between these 
alleles [110]. More importantly, this study showed the HLA-DRB5*01:01 
mediates the T-cell response initiated by the HLA-DRB1*15:01 and this 
epistatic interaction was linked to the less severe form of multiple sclerosis. 
Certain HLA allelic combinations, in particular the HLA class II region, are 
found at far higher frequency than the others in populations reflecting 
persistent selective pressure and such preferential allelic combination could 
be the effects of epistatic mechanism [111]. Interestingly, some of these 
haplotypes are associated to disease susceptibility such as the predisposition 
of the HLA-DRB1*04:01-DQA1*03:01-DQB1*03:02 haplotype to type 1 
diabetes and the HLA-B*57:01-C*06 to host control of HIV [112, 113].  
Besides the epistatic interaction between genes located within the MHC 
region; increasing there has been evidence for interaction of the HLA genes 
with genes outside of the region. Most notably is the association of HLA class 
I with the polymorphic KIR genes located on chromosome 19q13.4 whereby 
these genes encode activating and inhibitory receptors expressed on the NK 
cells.  Similar to the HLA loci, the diversity seen in the KIR genes is being 
maintained through pathogen mediated selection and specific HLA-KIR 
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combinations with NK activation properties are reported to confer resistance 
to infectious diseases [114]. For instance, the NK cells activations through the 
interactions of KIR3DL1 subtypes with HLA-B Bw4 alleles inhibit the HIV 
progression [115]. However, activating KIR-HLA pairings could also result in 
susceptibility to autoimmune diseases. Of prominence is the association of 
psoriasis with the HLA-C*06 alleles and KIR2DS1/KIR2DS2 [116, 117]. 
Overall, different KIR-HLA combinations give rise to variation in NK cells/T-
cells activation or inhibition; resulting in resistance and vulnerability against 
infection and autoimmunity. This KIR-HLA class I specificity is a classical 
example for genetic epistasis whereby the presence of genes encoding the 
specific alleles are essential for functional responses.   
 
1.9 Epigenetics 
To date, most of the MHC disease association studies are central on the 
differences in the nucleotide sequences; but in most cases how these 
sequence differences are mechanistically correlated to the disease is 
unresolved. The study of epigenetic in the MHC region could provide 
meaningful explanation to these associations given its importance to the 
regulation of gene expression. Indeed, it is now well-established that HLA 
class I and class II genes are regulated by epigenetic events [118].  With the 
exception of HLA-G, the HLA class I genes are regulated by a number of 
conserved promoter elements – enhancer A, interferon-stimulated response 
element (ISRE) and the SXY-module (Figure 1.9). Transcription factor 
nuclear-factor (NF)-kB binds to the enhancer A and interferon regulatory 
factor (IRF) family members binds to the ISRE; thus HLA locus specific 
sequence variation in the promoter region would induce differential activation 
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level among the HLA loci [119, 120]. The highly conserved SXY-module 
interacts with multiple transcription factors comprises of regulatory factor X 
(RFX), cyclic-AMP response element binding protein (CREB) and nuclear 
factor-Y (NF-Y) forming an enhanceosome that drive the genes transcription 
[121]. HLA-G, unlike other HLA class I loci, does not depend on the ISRE site 
for transcription regulation; instead it is regulated by CREB-1 and the 
transcription factor binding site is located further upstream (Figure 1.9) [122]. 
Under normal conditions, the expression of HLA-G is suppressed in most cell 
types other than trophoblast cells through chromatin remodeling via the 
transcription repressor Ras-responsive binding protein – 1(RREB-1) [123]. 
HLA-G expression is consistently found in tumor cells and thus it has been 
hypothesized that the expression HLA-G is a potential mechanism for the 
tumors to evade immunosurveillance [124, 125]. For the HLA class II genes, 
other than the presence of the SXY-module, their promoter region does not 
contain the enhancer A and ISRE (Figure 1.9). In fact, the transcription of 
HLA class II genes is controlled by the master activator class II transactivator 
(CIITA) [126]. In addition, the regulation of the class II genes is also 
associated with increase active histones modification and chromatin 
remodeling [127]. Other than the transcriptional regulation through cris-acting 
elements, it was found that the transcriptional insulator factor (CTCF) was 












Figure 1.9 An outline of the regulatory elements, transcription factors and 
epigenetic activities mediating the expression of HLA class I and class II 
genes. With the exception of HLA-G, all genes shared the SXY-module in the 
gene promoter region and interact with the enchanceosome complex to 









1.10 Genomic Modulators of Genes within MHC Region 
GWAS has successfully identified an abundance of new disease 
associated genomic loci in the MHC region that previously are undetectable 
using the traditional genomic approaches. However, in most cases, the exact 
location of the functional disease causative variants and how these 
polymorphisms affect gene expression leading to the observed disease 
phenotype remain unknown [129]. In addition, a number of these GWAS 
identified loci are found in the non-coding region and hence suggesting 
possible role in regulation of gene expression. Expression quantitative-trait 
mapping (eQTL) is one powerful tool to study the impact of sequence 
polymorphisms on transcription regulation. Indeed, many eQTL studies have 
showed strong associations in the MHC region [130-132]. More significantly, 
a recent study has demonstrated a HIV-1 control linked SNP located 35kb 
upstream of HLA-C is associated with differential HLA-C expression and it is 
later revealed that another variant linked to this SNP located at the HLA-C 
3’UTR mediates the binding of a microRNA resulting to variation in HLA-C 
expression [88, 133]. However, caution needs to be taken when analyzing 
eQTL associations in the MHC region. This is because conventional 
expression microarray is unable to fully account for the extreme 
polymorphism in MHC region and hence this may result in spurious eQTL 
associations. Nevertheless, these imply the effect of individual variations in 







1.11 Objectives of Thesis 
Several decades of research on the MHC region has outlined its genomic 
landscape providing extensive understanding to its gene organization, the 
linkage disequilibrium and haplotype structure. Indeed, important knowledge 
is gained in terms of its roles in the immune system, the nature and 
consequences of the extreme genetic polymorphisms in the region and its 
implication to numerous diseases. Despite the progress made, there is still a 
lack of understanding in (1) the biological and evolutionary mechanism driving 
the extreme genetic polymorphisms in the region, (2) the location of genetic 
variation with functional significance and (3) the underlying mechanism 
behind the numerous disease associations. The availability of MHC sequence 
information, in particular the structure and genomic organization of CEHs, is 
an essential resource to provide insights on above mention issues. 
1.11.1 Key Objectives 
1. Evaluate recombination profiles of HLA haplotypes from three distinct 
population groups and identify population-specific recombination sites. 
2. Determine the presence of conserved extended haplotypes (CEHs) in 
the Singaporean Chinese population. 
3. Establish an Asian reference MHC haplotype sequences. 
4. Examine multiple MHC CEH sequences with identical haplotype 
profile to explore the scope of intra-haplotypic conservation and 
variation. 
5. Determine the functional significance of intra-haplotypic variation. 
6. Determine the effect of haplotype sequence variations on the 





















2.1 Subjects and HLA Sequence-based Typing 
Peripheral blood mononuclear cells (PBMCs) were obtained with prior 
consent from 247 healthy Singaporean Chinese blood donors. Of these 211 
are unrelated individuals while 36 are from comprising members of family 
trios. The genomic DNA of this collection was kindly prepared and extracted 
by a previous post graduate student, Chia Jer-Ming. Subsequently, B-
lymphoblastoid cell lines (B-LCLs) were established from whole blood 
obtained from subjects who are HLA homozygous and the B-LCLs were 
prepared through in-vitro Epstein-Barr virus infection of the B-lymphocytes. 
The establishment of BLCLs were kindly performed and provided by WHO 
Immunology Center, National University of Singapore, Singapore. The two 
European B-LCLs - COX and QBL were purchased from the Research Cell 
Bank, Fred Hutchinson Research Centre, Seattle, WA. 
The HLA allelic type at HLA-A, -B, -C and –DRB1 loci of these 
Singaporean Chinese subjects were obtained from Yu et al [134].  This study 
used a sequence-based approach to interrogate the HLA allelic type. Briefly, 
the hyper-variable exons 2 and 3 of the HLA-A, -B, -C genes were examined 
by PCR amplification using specific primers, followed by direct DNA 
sequencing of the PCR products in the opposite directions. HLA-DRB1 was 
sequenced and typed as previously described [135]. Purified PCR products 
were sequenced using the ABI BigDye Terminator v3.1 chemistry run on an 
ABI Prism 3100 Genetic Analyser (Applied Biosystems, USA). Excess dye 
terminators were removed by purification using an ethanol/EDTA/sodium 





2.2 HLA Homozygous Cell Lines Culture and Treatment 
Under sterile conditions, frozen B58AL, B58SC, B58CF, B46BM, B46ZS, 
B46CM, COX and QBL B-LCLs were thawed in 37°C water bath and re-
suspended in 11ml of Roswell Park Memorial Institute medium supplemented 
with 10% Fetal Bovine Serum (RPMI/10%-FBS). Subsequently, centrifugation 
was performed at 800rpm for 5min and the resultant cell pellets were re-
suspended in 8ml RPMI/10%-FBS and moved into 25ml culture flasks. The 
cell cultures were then maintained at 37°C in a humidified incubator with 5% 
carbon dioxide in atmospheric air. When the cell confluency reached 85-
100%, the cell medium was changed and 2/3 of the cells were transferred to 
75ml culture flask and maintained at 37°C in humidified incubator with 5% 
carbon dioxide in atmospheric air. This process would be repeated till the 
number of cells required for experiments were attained. 
At the 5th passage, for each B-LCL, the cells were collected and counted 
at approximate 1 X 106 cells per ml. The cells of each B-LCL were then 
seeded in 6-wells plate and stimulated with 200nm phorbol 12-myristate 13 
acetate (PMA, Sigma) and 125nM ionomycin; equivalent amount of dimethyl 
sulfoxide (DMSO, Sigma) were added to unstimulated cell cultures to act as 
controls. Following, the cells were incubated for six hours in humidified 
incubator with 5% carbon dioxide in atmospheric air. After six hours, the 
culture were collected and pelleted down by centrifugation at 1000 rpm for 
5min, 4°C. 1.5ml of supernatant was then transferred to 2ml eppendorf tubes 
and stored at -80°C for the ELISA experiment while the remaining 
supernatant was discarded. Cell pellets were then re-suspended in 500ul of 
phosphate buffered saline (PBS); transferred to 1.5ml eppendorf tubes and 
centrifuged at 1000 rpm for 5min, 4°C. The supernatant was removed and the 
resultant cell pellets were stored in -80°C for subsequent RNA extraction. 
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2.3 DNA and RNA Extraction 
Genomic DNA was isolated from the cell pellets of B58AL, B58SC, 
B58CF, B46BM, B46ZS and B46CM BLCLs using the QIAGEN® DNeasy 
Blood and Tissue Kit; following the manufacturer’s protocol. Extracted 
DNA was elute in 200ul of 10mM Tris-Cl/0.5mM EDTA (AE buffer) and stored 
at -20°C. 
For the purpose of whole genome sequencing, high DNA quality and 
accurate quantification are important to achieve favorable sequencing results. 
To ensure these, gel electrophoresis run on a 0.8% agarose gel was 
performed to detect DNA degradation. The gel electrophoresis showed 
relatively tight band for the DNA of every cell line indicating that there was no 
or little degradation (Figure 2.1). The DNA quantification was performed using 
the Picogreen assay. Briefly, the quantification assay first requires the 
establishment of a 6-points DNA standard curve with concentration range 
from 0 to 10ng/ul of λ-DNA (Invitrogen, USA). DNA standards were generated 
from the 10X serial dilution of the 10ng/ul of λ-DNA working solution with the 
10mM Tris-Cl/1mM EDTA (TE buffer) and 10ul of the DNA standards was 

















Figure 2.1 Gel electrophoresis with 20ng of DNA per lane on 0.8% 









 Next, 100ul of 1X Picogreen (Invitrogen, USA) was then pipetted into 
each well and incubated at room temperature for 5 mins followed by 
centrifugation at 1000rpm for 30sec. Flurorescene output emitted from the 
interaction between the double-stranded DNA and Picogreen was measured 
using the Tecan Genios fluorescence reader (Tecan, Switzerland) and the 
fluorescence readings for the DNA standards were used to construct a 
standard curve. Lastly, using the same protocol, the concentration of the DNA 
samples were inferred by comparing their fluorescence readings against the 
standard curve. Overall, we were able to obtained at least 15ug of DNA for all 
the samples. 
Total RNA was extracted and purified using the RNeasy Mini Kit (Qiagen, 
Germany); following the manufacturer’s protocol. During the purification, 
additional steps for DNA digestion using the On-column DNase digestion kit 
(Qiagen, Germany) were included to ensure high quality RNA. The quality 
and quantity of the purified RNA were determined using the ND-1000 
Nanodrop spectrophotometer (Thermo Fisher Scientific, USA) and we were 
able to obtained at least 15ug of good quality total RNA for each sample to be 
used for RNA-sequencing. 
 
2.4 Enzyme-linked Immunosorbent Assay (ELISA) Experiment 
The amount of TNF-alpha and IL6 in the supernatant collected after six 
hours of PMA and ionomycin stimulated were determined by using the human 
TNF-alpha and IL6 Quantikine ELISA kits (R&D Systems). Briefly, samples 
were (200ul for TNF-alpha; 100ul for IL6) loaded in triplicates into the plate 
coated with mouse monoclonal antibody against the proteins together with the 
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assay diluent (buffered protein base with preservatives) provided, incubated 
for 2 hours and 1 hours at room temperature respectively and followed by the 
addition of the respective protein conjugate for additional 2 hour incubation at 
room temperature. The ELISA reaction was then detected by the additional of 
200ul of substrate solution (lyophilized NADPH with stabilizers) per well and 
incubated for 30min at room temperature in dark followed by the addition of 
50ul stop solution (2N sulfuric acid). The absorbance level was measured at 
450nm using the Infinite® 200 PRO plate reader (Tecan, Switzerland).  
The pates were washed five times with the washing buffer (1X buffered 
surfactant) after each step. The standard curve was established by an 8-
points serial dilution of 1X calibrator diluent to be used as a reference for 
quantification.    
 
2.5 RT-qPCR for ZFP57 Expression Quantification 
cDNA was generated using Maxima® First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific) as per manufacturer’s instruction using 1ug of total 
RNA as template. The reaction mixture comprised of 4ul of 5X reaction mix 
(reaction buffer, dNTPs, oligo dTs and random hexamer primers), 2ul of 
maxima enzyme mix (reverse transcriptase and RNase inhibitor), 1ug of total 
RNA and top up with nuclease-free water to 20ul. This was then incubated for 
10min at 25°C and followed by 15 mins at 50°C and at 85°C for 5 mins to 
terminate the reaction. The resultant cDNA was diluted 10 times with 
RNase/Dnase free water and stored at -20°C for subsequent use. 
qPCR by KAPA SYBR® FAST Roche LightCycler® 480 2X qPCR Master 
Mix  (Kapa Biosystems, Woburn, MA) was performed with triplicates for each 
of the two biological replicates on the Roche LightCycler® 480 System 
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(Roche Applied Science). The reaction mixture consisted of 5ul Sybr green, 
0.5ul of combined forward and reverse primer (2ng), 2ul of cDNA and 2.5ul of 
nuclease-free water. The qPCR cycling conditions were set at 95°C for 10 
mins, 45 cycles of [95°C for 10 secs; 60°C for 10 seconds; 72°C for 10 
seconds] and followed by 95°C for 60 seconds. Ct values calculation using 
the second derivative maximum method and melting curve analysis were 
carried out with gene-specific primer pairs. The ZFP57 expression was 
normalized to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) and 
determined using the ΔCt method.   Primer pair sequences for the respective 






Table 2.1 Primer sequences for ZFP57 and HPRT1 gene. 
Gene Forward Primer Reverse Primer 
ZFP57 TGAGGATGTGGCAGTGAATTT GTGTTTGGGAGATGGACAAAC 








2.6 Elucidation of RCCX Copy Number Variations (CNV) in the Cell 
Lines 
The assay used to determine the RCCX modular duplication in each cell 
line was based on and developed from a modified version of the real-time 
PCR assay as previously described in Wu et al [136]. This modified version 
used SYBR Green chemistry instead of Taqman chemistry to measure the 
level of mRNA. Primers specific for C4A, C4B, long C4 (C4L), short C4 (C4S) 
were designed to resolve the RCCX modular duplication (Table 2.2). The 
difference between C4L and C4S is the insertion of the endogenous retrovirus 
HERV-K segment between exon 9 and exon 10. As such the amplicons for 
C4L and C4S shared a common forward primer, and their reverse primers 
were designed to differentiate between the long and short C4 gene (Figure 
2.2). In addition, the copy number of the TNXA gene, which equals to the 
number of RCCX modules minus 2, was also interrogated. The assignment 
for the number of copies of each targeted gene involved two calibration steps. 
The first calibration step was a quantitative real-time PCR endogenous 
control using the RP1 gene, which is positioned upstream of the RCCX 
module and always present as 1 copy per chromosome.  Quantified levels of 
target genes were compared to levels of RP1 in order to obtain relative copy 
numbers of target genes. However, in this approach, there is an intrinsic 
underestimation of the targeted gene copy number. To correct for this 
underestimation, a second calibration step was performed. A calibrated plot 
created from 13 reference human cell lines (COX, QBL, MOU, PGF, SSTO, 
DBB, WT51, MADURA, CB6B, WT8, DAUDI, MANIKA and HOM) with known 
RCCX modular number was used to unambiguously assign the targeted gene 
copy number (Table 2.3).  
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The genomic DNAs of these reference cell lines were purchased from the 
Research Cell Bank, Fred Hutchinson Research Centre, Seattle, WA.  For 
each sample, the number of copies of (C4A + C4B)/2, (C4L + C4S)/2, and 







Table 2.2  Primer sequences to determine the copy numbers of the C4A, 
C4B, C4 long, C4 short, TNXA and RP1 genes.  
Gene  Forward Primer Reverse Primer 
C4A CCTTTGTGTTGAAGGTCCTGAGTT TCCTGTCTAACACTGGACAGGGGT 
C4B TGCAGGAGACATCTAACTGGCTTCT CATGCTCCTATGTATCACTGGAGAGA 
C4L TTGCTCGTTCTGCTCATTCCTT GTTGAGGCTGGTCCCCAACA 
C4S TTGCTCGTTCTGCTCATTCCTT GGCGCAGGCTGCTGTATT 
TNXA TCCTGCAGTCATCTTTGTCTTCAG GAGCTGCAGATGGGATACCTTTAA 














Figure 2.2 Verification of the copy numbers of C4L and C4S genes. An 
insertion of the endogenous retrovirus HERV-K segment is found in C4L but 
not C4S. To differentiate the two genes, the reverse primer for the C4L 
amplicon targets the 5’ sequence specific to HERV-K (red) while the reverse 
primer for the C4S amplicon targets the upstream sequence of exon 10 


















Table 2.3 RCCX modular structure in 13 reference human cell lines to 
establish the calibration plot. 
Cell line  RCCX Structure C4A C4B C4L C4S TNXA 
COX 
Monomodular  
0 2 0 2 0 
QBL 2 0 2 0 0 
MOU 0 2 2 0 0 
PGF 
Bimodular  
2 2 4 0 2 
SSTO 2 2 4 0 2 
DBB 2 1 2 2 2 
WT51 4 0 4 0 2 
MADURA 2 2 0 4 2 
CB6B Quadrimodular  4 4 6 2 6 
WT8 
Heterozygous 
1 2 3 0 1 
DAUDI 2 1 2 1 1 
MANIKA 2 3 2 3 3 











2.7 SNP Genotyping and Selection 
SNPs interrogation of MHC region in the Singapore Chinese (CHSG) 
population was performed on the Illumina GoldenGate MHC Panel platform 
(Illumina, USA). This platform was designed examine the genotype of 2360 
SNPs residing in the MHC genomic region from chr6:28.97 – 33.88Mb. The 
SNP coordinates were mapped to the Human Reference Sequence Assembly 
36.1 (NCBI 36.1). Genotyping results were filtered using the following criteria: 
SNP loci deviating from Hardy Weinberg equilibrium using a Fisher’s exact 
test at a significance level of 0.001; SNPs loci with a call rate of less than 
95% and SNP loci with a minor allele frequency of less than 5% were 
discarded. In addition, for familial data, SNP genotypes that were discordant 
with the parental structure in more than one family were discarded. After the 
quality control checks, 1877 SNP loci were left for further analysis. 
Genomic DNA of the six samples (B58AL, B58SC, B58CF, B46ZS, 
B46BM and B46CM) was subjected to genome-wide SNP genotyping using 
the Illumina Human 1M-Duo BeadChip Kit (Illumina, USA). The genotype 
profiles of 1,169,675 SNPs across the entire human genome were 
interrogated. The SNPs coordinates were mapped to the Human Reference 
Sequence Assembly 37.2 (NCBI build 37.2), and all samples had overall call 
rates of more than 95%. SNP loci that were not called in any of the samples 
or that deviated from Hardy Weinberg equilibrium at a significance level of 






Genotype data consisting of 30 European (CEU) trios and 30 Yoruban (YRI) 
trios were obtained from the HapMap phase II collection [137]. SNPs 
genotype data within the MHC region interrogated by the Illumina GoldenGate 
assay were selected and subjected to the screening procedure as described 
above. A total of 1360 common SNPs loci found across the CEU, YRI and 
CHSG populations were chosen for further downstream analysis.  
 
2.8 Haplotype Inference 
Haplotype inference was carried out using a Bayesian-based approach 
implemented in PHASE 2.1 [138, 139]. This approach computes the posterior 
distribution of unknown haplotypes based on the observed SNPs genotype to 
estimates the expected haplotype structures found in the sample population 
(prior information). This prior information is estimated using the coalescent-
based model where recent haplotypes are derived from the ancestor 
haplotypes through recombination and mutation; as these events are 
relatively rare over short genetic distances, new haplotypes will resemblance 
to one of the observed haplotypes in the population [140]. Haplotypes for 
each individual is then inferred by selecting the most probable haplotype from 
the posterior distribution. Among the population-based haplotype inference 
algorithm, PHASE 2.1 is considered as the benchmark for haplotype phasing 
[141] and hence was selected. To ensure maximum accuracy, several factors 
that influence phasing accuracy [142] were taken into consideration. Rare 
SNP loci which are computationally difficult to resolve, would not be 
considered and in addition, the phasing procedure for each population group 
was performed independently to preserve the ethnic relatedness. For the 
Singapore Chinese population, the haplotype inference was performed in 2 
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stages. First stage involved the phasing of 12 family trios to attain 48 distinct 
phase unambiguous haplotypes. Second, this set would serve as “known 
haplotypes” to aid the haplotype inference for the 211 unrelated individuals. 
Each of the HLA alleles was represented by unique digit and the haplotype 
information was resolved together with the SNPs. The HapMap populations 
HLA-A, -B and –C typing were attained from  [143] and phased together with 
the selected SNPs. 
 
2.9 Extended Haplotype Homozygosity (EHH) and Recombination 
Analysis 
EHH analysis was performed to assess the level of LD decay across a 
sample of haplotypes tagged with their respective HLA alleles. Essentially, 
EHH calculated at a position x is defined as the probability that 2 
chromosomes, carrying an allele (or haplotype) of interest at an anchor locus, 
have identical SNPs sequence from defined core locus to the position x [144].  
In the context of this project, this core locus is described by the HLA allele of 










The EHH of a selected core locus t is computed as the following: 
𝐸𝐻𝐻𝑡 = ∑ �𝑒𝑡𝑖2 �𝑆𝑖=1 �𝑐𝑡2 ��     
c is the number of haplotypes of a particular HLA allele 
e is the number of total number of haplotypes 
s is the number of haplotypes with a unique SNPs sequence 
 
A constant EHH value indicates the transmission of a haplotype without 
recombination. Hence, probable recombination sites were scored when either 
EHH decay is observed in 2 or more HLA haplotypes across the SNPs 
interval or when at least 10% of a single HLA haplotype diverged from the 
core haplotype. 
The historical recombination rates for HLA chromosomal SNPs 
haplotypes were estimated using the program LDHat [145]. LDHat 
implements a coalescent-based approach that accounts for the patterns of 
genetic variation and observed linkage disequilibrium to infer recombination. 
The estimate was performed with a block penalty of 5 and 10,000,000 
iterations. LDHat presents the population-scaled recombination rates ρ, 
hence to obtain the per-generation recombination rates r (cM/Mb), the 
following equation was applied. 
𝑟 = 𝜌 4𝑁𝑒�     





2.10 Runs Of Homozygosity (ROH) and Identity-By-Descent (IDB) 
Analysis 
The genomic region in chromosome 6 from 25MB to 35MB covering the 
extended MHC region was selected and screened for Runs Of Homozygosity 
(ROH) segment analysis. The ROH analysis was implemented by an 
algorithm in the PLINK package [149] with the following parameters - sliding 
window size : 50kb, minimum length for ROH segment : 1000kb, number of 
heterozygotes genotype call allowed in a window : 3 and maximum distance 
between adjacent SNPs in order to be considered in a segment : 50kb. The 
genotype data of B58AL, B58SC, B58CF, B46ZS, B46BM and B46CM 
assayed from Illumina Human 1M-Duo BeadChip were used for ROH 
analysis. In total, 10215 SNPs markers were found within the genomic region 
of interest and were used for the ROH analysis. 
Similarly genotype information of the six cell lines from the Illumina 
Human 1M-Duo BeadChip was used for the Identity-By-Descent (IBD) 
analysis. 96,387 independent SNPs not in linkage disequilibrium with one 
another were randomly selected from the genome-wide SNPs data and were 
used to test for IBD among the samples. The PLINK package was used to 
estimate the following IBD parameters in each sample pair: probability of 
genetic markers sharing 0 allele (IBD=0), probability of genetic markers 
sharing 1 allele (IBD=1) and probability of genetic markers sharing 2 alleles 
(IBD=2). Therefore, high values of IBD=1 and IBD=2 would denotes high 






2.11 Genome Sequencing 
The genomic DNA extracted from B58AL, B58SC, B58CF, B46BM, 
B46ZS and B46CM BLCLs was subjected to whole genome sequencing using 
the next generation technology implemented by Complete Genomics 
(Mountain View, CA, USA). The sequencing was performed using Complete 
Genomics (CG) proprietary sequencing instruments and technology [150]. 
Briefly, the CG sequencing technology called DNA nanoball sequencing 
involves the searing of the isolated DNA into approximately 500bp genomic 
fragments; the insertion of four synthetic adaptor sequences into each 
fragment followed by the circulation of the fragments to generate 70-base 
reads (35-base pair-end reads). Each of these circular reads is then amplified 
into a head to tail concatemer resulting in a long single-strand DNA. This 
single-stranded DNA are folded in a nanoball and captured by a microarray 
sequencing flow cell. The sequencing assay called combinatorial probe-
anchor ligation (cPAL) chemistry is carried out where independent non-
iterative sequencing reactions interrogate the nucleotide profiles of the DNA 
through the ligation of fluorescent probes to the DNA. There are several 
advantages of the CG technologies over approaches that employed 
sequencing by hybridization method. Firstly is the ability to interrogate simple 
repeats. Secondly, the independent non-iterative sequencing reaction 
minimizes the accumulation of sequencing errors and provides superior fault 
tolerance. Lastly, the cPAL approach enable massive parallel base reading in 
a single cycle and therefore reduces the consumption of reagents and 




The CG proprietary bioinformatics pipeline was used to map and assemble 
the genome [151] and the reads were aligned to the Human Reference 
Sequence Assembly 37.2 (NCBI build 37.2). Using a combination of Bayesian 
and de Brujin graphed-based approaches, the CG assembler is able to 
annotate SNPs, short insertion/deletions and block substitutions. The variants 
called were annotated against a variety of public databases - NCBI gene 
annotation Build 37.2, dbSNP build 137, catalogue of somatic mutations in 
cancer v61 (COSMIC) and miRBase version 19 and Data of Genomic 
Variants version 9 (DGV). 
 
2.12 MHC Haplotype Variation Classification and Comparison 
For intra-haplotype comparisons, only nucleotides at positions with high 
quality score metric generated from the CG assembly protocols were 
considered for comparison; nucleotide at positions with low confidence score 
were considered as an ambiguous call and would not be used for 
comparison. Consensus sequence for each of the two Asian MHC haplotypes 
was established by evaluating the samples sequences. For each haplotype, 
the 3 genomes available were each divided into two haploid chromosomes, 
and the 6 resulting haploid chromosomes were then compared.  If 2 or more 
chromosomes had ambiguous or low confidence calls at a position, it was no-
called (N) in the consensus sequence.  A variant was called if two or more 






To compare the two Asian haplotypes against the eight European MHC 
haplotypes sequenced by the MHC Haplotype Project, BED files of the eight 
European MHC haplotypes [14-16] were downloaded 
from http://www.ucl.ac.uk/cancer/medical-genomics/mhc/#HaplotypeData and 
the coordinates of these BED files were aligned to the Human Reference 
Sequence Assembly 37.2 (NCBI build 37.2). Genetic variants found between 
the MHC haplotypes were annotated using the annovar software [152]. 
Construction of the consensus sequences as well as the intra and inter-
haplotype comparisons were performed using in-house generated R-scripts. 
 
2.13 Assessment of Sequencing Accuracy 
To assess the discordant in the nucleotide calls generated from the CG 
platform and the SNPs genotyping platform, a total of 48 nucleotide positions 
were selected for PCR re-sequencing. Primer pairs to assess the variant of 
interest were designed using NCBI Primer-BLAST and checked against 
Human Reference Sequence Assembly 37.2 (NCBI build 37.2). Only primer 
pair’s sequences matching to the sequence of the samples were selected. 
This cross-checking of primer sequences with the sample genomes was 
performed using in-house written R-scripts. The sequences of these primer 
pairs and the location of the variants can be found in Table 2.4. The PCR 
reactions were carried out in volume of 20ul reaction mixture comprising of 
2ul of 10X buffer (100mM Tris-HCl and 500mM KCl), 2.4ul of 25mM MgCl2, 
1ul of 2.5mM dNTPs, 0.2ul of Hi Fidelity Taq DNA polymerase (Roche 
Applied Science, Germany), 3ul of 2ug forward primer, 3ul of 2ug reverse 




 Table 2.4 Re-sequencing experiments to assess mismatches between 
SNP genotyping and CG sequencing platform in cell lines carrying A33-B58-
DR3 and A2-B46-DR9. Ta: annealing temperature. 
A33-B58-DR3 
    
Forward Primer Reverse Primer 
Position 












































CAAGTTCCATT  33,036,549 560 59 
     A2-B46-DR9 
    
Forward Primer Reverse Primer 
Position 






































The PCR reactions were performed on Applied Biosystems® GeneAmp® PCR 
System 9700 machine (Applied Biosystem, USA).  The following cycling 
conditions were used: 94°C for 2 mins, [94°C for 30 seconds, annealing 
temperature (Ta) for 30 seconds, 72°C for x seconds (dependent on the 
length of template)] for 25 cycles, and 72°C for 20 mins. The quality and 
integrity of the PCR product was verified by 1% agarose gel electrophoresis. 
The PCR products were then purified using the QIAquick gel extraction kit 
(Qiagen, Germany) according to the manufacture’s protocol and the purified 
PCR templates were sequenced using their respective primers. 
Primer sequences AGCAGTCACAAGTCACAGGG and 
CAGCCCATCGCATGCTCAAT were used to interrogate the missense 
mutation (chr6:29,913,037, HLA-A exon 7) found in the cell lines carrying 
A33-B58-DR3 was selected. TA-cloning was then performed to verify the 
missense mutation using pGEM®-T Easy Vector Systems (Promega, 
Fitchburg, WI) following manufacturer’s instructions. Briefly, 3ul of purified 
PCR product were ligated with 1ul of pGEM®-T Easy Vector in a reaction 
mixture comprising of 5ul of 2X ligation buffer and 1ul of T4 DNA ligase and 
this reaction mixture was incubated for 1 hr at room temperature. Next, 
transformation was performed using the JM109 High Efficiency Competent 
Cells where 1ul of the ligated products were added into 50ul of JM109 and 
the mixture was incubated on ice for 20 mins; followed by heat shock for 45 
sec at 42°C and immediate incubation for 2 mins on ice. The recovery of the 
cells was performed by the addition of 950 ul of S.O.C medium (Invitrogen) 
and the reaction mixture was incubated in thermo-mixer shaking at 1400rom 
for 1 hr at 37°C. 100ul from the reaction mixture was plate on 
LB/ampicillin/IPTG/ X-Gal plate and the plate was incubated overnight at 
37°C. Thereafter white colonies were selected, inoculated in 3ml of LB with 
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100ug/ml of ampicillin and incubated with shaking overnight at 37°C. Plasmid 
DNA was extracted using QIAprep® Miniprep Kit (Qiagen, Germany) and 
isolated plasmids were sequenced with the T7 promoter and SP6 promoter 
primers. 
 
2.14 Phylogenetic Analysis and Estimation of Haplotype Divergence 
The SNP sequences of the Asian and European haplotypes spanning 
across the extended MHC region (chr6: 29.65-33.0Mb) were comprise of 
18,781 common SNPs annotated in dbSNP build 137. SNP positions with 
heterozygous call in the Asian haplotypes were denoted as missing data. 
Phylogenetic trees were constructed based on the maximum likelihood 
statistical method and the Kimura 2-parameter substitution model was used to 
calculate the likelihood on a given tree. To evaluate the reliability of branching 
points, bootstrap test of phylogeny was performed (n=500). The tree building 
process was implemented in MEGA5 [153].  
 
Nucleotide diversity metric (π) was used to measure the level genetic 
variation between the MHC sequences computed by the following equation. 
π = 2∑ ∑ xixjπiji−1j=1ni=1     
n is the number of sequences 
x is the frequency of the ith and jth sequences 





The age of the Asian haplotypes was determined by the following equation. 
𝑡 = 𝑁𝑦 𝑛𝐿𝑢�     
t is the length of time since the haplotype sequences shared a common 
ancestor 
N is the number of nucleotide differences between the haplotype sequences 
y is the number of years per generation and was set at 20 years 
n is the number of haplotype sequences  
L is the length of the sequences 
u is the mutation rate per nucleotide per year and was set at 1.1X10-8 [154] 
 
2.15 RNA-seq Preparation and Analysis 
Total RNA of at least 15ug isolated from B58AL, B58SC, B46BM, B46ZS, 
COX and QBL cell lines were subjected to RNA-seq. Prior to the library 
construction step, cytoplasmic rRNA were removed from the RNA samples 
using the human Ribo-ZeroTM rRNA Removal Kits (Epicentre, USA). For each 
RNA sample, total RNA libraries of 75bp pair-end reads with DNA fragments 
size range 120-225bp were prepared using the TruSeq RNA kit (Illumina, 
USA). A total of 12 libraries were prepared including libraries for the sample 
biological replicates. Sequencing was carried out on the Illumina HiSeq 2000 
machine with two libraries pooled together per sequencing lane, resulting in 
approximately 79 million reads per library. The library preparation and 





Quality control (QC) was performed on the raw sequence data to remove low-
quality reads. Here, only reads with reads with 70% of the base positions 
meet the Phred score cuff-off of 20 were retained for the further downstream 
processes. This filtering was conducted using the NGS QC Toolkit [155] and 
the sequence biasness was assessed using the FastQC software 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). 
The QC reads from each library were mapped independently using 
TopHat2 v2.0.7 [156] against the human reference transcriptome (NCBI gene 
annotation Build 37.2) and the human reference genome (NCBI Build 37.2 
reference sequence) using the default settings. The transcripts annotation 
GFF file and sequence indexes information were downloaded from Illumina’s 
iGenomes project (ftp://ussd-ftp.illumina.com).  The TopHat2 alignment 
algorithm involves a three-step process. First the reads are mapped against 
the known transcriptome. The remaining unmapped reads are then mapped 
against the genome; reads that are spanned within a single exon are treated 
as mapped reads while multi-exon spanning reads are treated as unmapped 
reads. Together with previously aligned reads with low scores, the third step 
will split the unmapped reads into non-overlapping 25bp segments and 








To estimate the relative abundance of the transcripts, the approach 
implemented in the Cufflinks suite (version 2.1.1) software was used [157]. 
RNA-seq enables quantitative measure on the abundances of RNA 
transcripts in the form of the number of reads mapped to the targeted 
transcripts. However, because of the inherent technical biases introduced in 
the library preparation step and the variation in the number of reads 
generated between different sequencing runs as well as due to the difference 
in the length of the RNA transcripts, normalization procedure is essential to 
attain meaningful interpretation from the analysis. To account for these 
issues, Cufflinks uses fragments per kilo base of transcript per million 
mapped reads (FPKM) that normalized the read counts by the length of the 
transcripts and the total number of mapped reads in the sample. Cufflinks 
were performed with the NCBI gene annotation Build 37.2 to output FPKM 
values for known annotated genes. For differential expression analysis, we 
used Cuffdiff in the Cufflinks suite to perform the estimation. In Cuffdiff, genes 
variance across replicates is modeled as a non-linear function of mean counts 
using a combination of normal and negative binomial distributions and T-test 
is used to derive the P-values for differential expression. To correct for 









2.16 Databases and Tools 
Allele Frequency Net Database (AFND) 
The AFND [158] was used to search and extract the HLA allele and HLA 
haplotype frequencies in worldwide populations. 
(http://www.allelefrequencies.net/)  
The International Immunogenetics Information System®  HLA 
(IMGT/HLA) 
The HLA allele sequences used in this study was extracted from the 
IMGT/HLA [11] (http://www.ebi.ac.uk/ipd/imgt/hla/, Release 3.13.1).  
UCSC Genome Browser 
The ENCODE histone modification data was assessed through the UCSC 
Genome Browser (http://genome.ucsc.edu/). In addition, the Table Browser 
tool in the genome browser was used to retrieve the Human genome 
reference sequence and annotation data in the MHC region as well as to 
extract the SNPs information residing in the eight alternate MHC reference 
sequences. 
International HapMap Project 
The genotype data of the European population (CEU) and Nigeria 
Yoruba population (YRI) were obtained from the HapMap database 
(release 24). The data was QC and all the SNP alleles were all referred 
to the positive strand before analysis.    
Gene Expression Omnibus (GEO) 
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The expression profiles of the BLCLs from the Centre d'Etude du 
Polymorphisme Humain (CEPH) collection under the accession number of 
GSE29158 were extracted from the GEO database. 
R Project for Statistical Computing 
The R programming environment was used to perform data processing and 
graphics plotting. R packages were also used for basic statistical analysis. 
NGS tools 
The Integrative Genomics Viewer (IGV) [159] was used to view and check on 
the RNA-seq reads mapping results. The SAMtools - version 0.1.18 
(http://samtools.sourceforge.net/) and Picard 
(http://picard.sourceforge.net/index.shtml) were used to manipulate and 


















Recombination in the Major 




















3.1  Introduction 
Recombination has a significant role in the generation of high haplotype 
diversity found within the human MHC region. The occurrence of these 
recombination events enables the assortment of DNA blocks within the MHC 
region [10] and in the process creating diverse combinations of MHC 
haplotype across populations. Typically, recombination sites are localized to 
within a 1 – 2kb genomic segment that is flanked by regions with low 
recombination [160] and are found at multiple points along the chromosomes 
in a non-random manner. These would lead to the breakdown of linkage 
disequilibrium (LD) defining the discrete haplotype blocks [161].  
As compared to other parts of the genome, the identification of 
recombination sites within the MHC region is proven to be particularly difficult. 
Previously, the laboratories of Mary Carrington and Alec Jeffreys employed 
single-sperm genotyping approach to detect the frequency and distribution of 
recombination within the MHC region and these studies were able to definitely 
identify six MHC-residing recombination sites [47, 48]. However, this 
approach is experimentally laborious and the resolution of the identified 
recombination sites (average 73.2kb segment per site) is poor. The 
availability of high-throughput single nucleotide polymorphism (SNP) 
genotyping assay has provided an alternate method to infer local 
recombination rates through in silico modeling using population genotype 
SNPs information. This approach is best exemplified by the undertaking of the 
International HapMap Project where 3.1 million SNPs information extracted 
from individuals of European, African and Asian ancestries was used to 
characterize the patterns of LD in the human genome and provide means to 
estimate recombination rates [160]. However, this approach of using admixed 
population data to infer recombination sites is not comprehensive enough 
when applied to the MHC region. This is because the intense genomic 
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rearrangement in the MHC region, not found in other parts of the human 
genome, is driven by the underlying HLA allelic gene combinations which are 
uniquely found in distinct population groups complicates the mapping of 
recombination sites in the human MHC region [162, 163]. Population-distinct 
HLA allelic gene combinations maintained by natural selection and other 
evolutionary forces may result in recombination breakpoints specific to each 
population. Hence, the exclusion of HLA allelic typing information in the 
recombination sites inference process could possibly conceal the presence of 
population-specific recombination sites.    
In this chapter, we devised a method to detect the location and the 
frequency of recombination sites within the MHC region. This approach relied 
on the LD genetic map generated using both the HLA allelic information and 
the SNPs haplotype phase information from an Asian cohort comprising of 
Singapore Chinese (CHSG) to infer MHC-residing recombination sites. Using 
this approach, we also examined the recombination profiles in individuals of 
European and African ancestries, and hence offered a comprehensive MHC 













3.2  Results 
 
3.2.1  Linkage Disequilibrium Structure within MHC Region 
The inference of recombination sites would require the generation of 
population LD structure.  To perform this, individuals HLA allelic typing and 
the MHC region SNPs genotype information are essential. The HLA 
information of 247 CHSG individuals (211 unrelated and 36 comprising 
members of family trios) were obtained from Yu et al [134] and they were 
typed for four HLA loci at HLA-A, -B, -C and –DRB1 using sequence-based 
typing method. DNA of the same cohort was then subjected to Illumina 
GoldenGate MHC Panel to interrogate the SNPs genotype status covering 
4.9Mb (28,970,148 - 33,882,048) of the extended MHC region. By 
incorporating both the HLA allelic and SNPs genotyped data, SNPs 
haplotypes phase with their corresponding HLA allelic gene combination were 
derived using PHASE 2.1 [138]. The resulting 470 chromosomes were 
categorized according to their HLA alleles and haplotypes. The most frequent 
HLA haplotypes found in the CHSG population were A*02:07-C*01:02-
B*46:01 (12.8%), C*01:02-B*46:01-DRB1*09:01 (9.6%), A*33:03-C*03:02-
B*58:01 (9.0%), C*03:02-B*58:01-DRB1*03:01 (7.7%), A*02:03-C*07:02-
B*38:02 (4.3%), A*11:01-C*07:02-B*40:01 (4.0%), C*08:01-B*15:02-
DRB1*12:02 (3.6%) (Table 3.1). SNPs haplotypes pooled according to their 
HLA alleles with frequency > 5% were then subjected to extended haplotype 
homozygosity (EHH) at three separate 1 mega-base genomic segments 
(chr6: 29.5 – 30.5 Mb, chr6: 31.0 – 32.0 Mb and chr6: 32.2 – 33.2Mb) 
covering the HLA genes loci. EHH is the measure of LD decay at varying 
locations from a defined locus [144] and hence provides an overview on the 




Table 3.1   Common HLA haplotype frequency in CHSG (A) 3-locus HLA-
A-C-B (B) 3-locus HLA-C-B-DRB1 (C) 4-locus HLA-A-C-B-DRB1 
 
A HLA-A-C-B 
 Haplotype  Counts Observed Freq. (%) 
 A*02:01-C*07:02-B*40:01 7 1.49 
 A*02:01-C*15:02-B*40:01 8 1.70 
 A*02:03-C*07:02-B*38:02 20 4.26 
 A*02:07-C*01:02-B*46:01 60 12.77 
 A*11:01-C*03:04-B*13:01 15 3.19 
 A*11:01-C*08:01-B*15:02 16 3.40 
 A*11:01-C*07:02-B*40:01 19 4.04 
 A*11:01-C*01:02-B*46:01 10 2.13 
 A*11:02-C*12:02-B*27:04 7 1.49 
 A*24:02-C*03:04-B*40:01 7 1.49 
 A*24:02-C*07:02-B*40:01 8 1.70 
 A*33:03-C*03:02-B*58:01 42 8.94 
 
B HLA-C-B-DRB1 
 Haplotype  Counts Observed Freq. (%) 
 C*03:04-B*13:01-DRB1*15:01 12 2.55 
 C*03:04-B*13:01-DRB1*16:02 7 1.49 
 C*08:01-B*15:02-DRB1*12:02 17 3.62 
 C*07:02-B*40:01-DRB1*09:01 15 3.19 
 C*01:02-B*46:01-DRB1*08:03 13 2.77 
 C*01:02-B*46:01-DRB1*09:01 45 9.57 
 C*03:02-B*58:01-DRB1*03:01 36 7.66 
 
C HLA-A-C-B-DRB1 
 Haplotype Counts Observed Freq. (%) 
 A*02:03-C*07:02-B*38:02-DRB1*16:02 7 1.49 
 A*02:07-C*01:02-B*46:01-DRB1*08:03 8 1.70 
 A*02:07-C*01:02-B*46:01-DRB1*09:01 36 7.87 
 A*11:01-C*03:04-B*13:01-DRB1*15:01 7 1.49 
 A*11:01-C*08:01-B*15:02-DRB1*12:02 12 2.55 
 A*11:01-C*07:02-B*40:01-DRB1*09:01 7 1.49 






In this study, the core locus for the three respective genomic segments was 
defined at the HLA-A, HLA-B and HLA-DRB1. Generally, the EHH value of a 
HLA haplotype recorded a drop, at incremental distance away from the 
defined core HLA locus, whenever there is decay in LD.  Unchanged EHH 
values over long genomic distance imply regions of high LD and sequence 
conservation. 
Region of high LD with EHH >= 0.9 were observed in extended regions 
proximate to the HLA-A, HLA-B and HLA-DRB1 genes (Figure 3.1). At the 
chr6: 29.5 – 30.5 Mb chromosomal segment, a 190kb (position 29,838,709 – 
30,027,753) region of extensive LD encompassing HLA-A, HLA-H and HLA-G 
was observed (Figure 3.1A). Haplotypes telomeric of HLA-A were generally 
well conserved while at the centromeric end, two distinct patterns emerged. 
Although HLA-A*02:07 and A*33:03 haplotypes stretched a further 200kb or 
more before breaking up, haplotypes carrying A*02:01, A*24:02, A*11:01 
alleles broke right after HLA-A. For the chr6: 31.0 – 32.0 Mb chromosomal 
segment (Figure 3.1B), high LD was observed for at least 213kb (position 
31,325,794 - 31,538,700) in all the common HLA-C-B haplotypes. This region 
of strong LD extended past HLA-C towards the telomeric end, and stretched 
over the MICA gene at the centromeric end. Of note, the centromeric 
boundary whereby all HLA-C-B haplotypes break corresponded to a HapMap 
inferred recombination region at position 31.54 Mb. The region of strong 
homozygosity at the chr6: 32.2 – 33.2Mb segment stretched for at least 
181kb and was flanked by 2 recombination sites derived from the sperm 
typing assay (Figure 3.1C) [47]. The sperm typing recombination site at the 
telomeric end spans over a 105.15kb region enveloping several EHH drops. 
The most significant EHH drop was found at the 32,447,054 to 32,448,850 





Figure 3.1 Extended haplotype homozygosity (EHH) plots of SNP 
haplotypes for common HLA alleles. Plots covering 1Mb region with the 
classical HLA loci/haplotypes used as anchor positions: (A) HLA-A, (B) HLA-
C-B and (C) HLA-DRB1 respectively. Positions of recombination sites and 
their relative sizes are mapped onto the plots as follows: six recombination 
segments identified by sperm recombinants (highlighted in pink columns) and 




At the centromeric end, 5/7 HLA-DRB1 haplotypes registered EHH drops at 
the same location that coincided with the sperm typing derived recombination 
interval (position 32,447,054 - 32,448,850). 
 
3.2.2 MHC-residing Recombination Sites within the CHSG Population 
LD breakages denoted by decay of EHH values along the chromosome is 
indicative of probable occurrence of recombination events. The EHH plots of 
the three genomic segments were marked by distinct step-wise drops 
occurring at non-random discreet interval (Figure 3.1), suggesting the 
presence of recombination sites. Putative recombination sites are recorded 
only either when two or more HLA haplotypes independently register drop in 
EHH value across the same SNPs interval or when at least 10% of the 
chromosomes carrying a unique HLA allelic haplotype diverge from the core 
pool. In addition, in silico recombination rates estimation using LDhat [145] 
was performed based on the pooled 470 chromosomes.  
A total of 69 recombination sites were characterized across the three 
genomic segments based on the above criteria (Figure 3.2 and Table 3.2). In 
contrast, the approach using the sperm typing assay and the HapMap study 
were only able to detect six and 29 recombination sites across the extended 
MHC region respectively. All the six sperm typing sites overlapped with EHH 
drops and as the sperm typing approach had poor resolution ranging in size 
from 35.4kb to 116.3kb; it was not uncommon to see several EHH drops 









Figure 3.2 Recombination regions identified by SNPs interval displaying 
EHH decay. Plots illustrate the number of unique HLA allelic haplotypes 
independently registered drop in EHH (red) and the recombination rates 
(blue) across (A) HLA-A, (B) HLA-C-B and (C) HLA-DRB1. Recombination 
segments identified by sperm recombinants are indicated by the pink colored 
bars and the HapMap-inferred recombination sites are indicated by the blue 






Table 3.2 List of the recombination sites identified through the EHH 
approach. 69 recombination sites were identified and among them, 37 were 
not found in any of the previous studies. 
 
From  rsID  To  rsID  Size Marker 
* 29591947 rs1592410 29594887 rs9257890 2.94 LOC100507362  
 29622209 rs398616 29624221 rs3094576 2.01 UBD 3’  
 29630691 rs2534791 29634919 rs362536 4.23 UBD Intronic  * 29637733 rs1233405 29641274 rs388234 3.54 UBD 5’  
 29648840 rs362509 29651625 rs362525 2.79 GABBR1 3’  
 29677934 rs3025643 29679588 rs10946999 1.65 GABBR1 Exon  † 29769435 rs7772169 29772431 rs3131886 3 MOG 3’  
† 29791787 rs1632962 29792613 rs2517911 0.83 HLA-F  
 29803481 rs1628578 29804097 rs3817826 0.62 HLA-F-AS1 
 29830494 rs9391630 29838709 rs1737069 8.22 IFITM4P  † 29946621 rs2844821 30007656 rs2524005 61.04 HLA-H-HCG4B  
 30027753 rs7747114 30032404 rs3893538 4.65 HLA-A  
 30038598 rs7739434 30040979 rs3873283 2.38 HCG9 5' 
 30154225 rs2394734 30155944 rs7382061 1.72 GABRA3 * 30179089 rs2240070 30184609 rs2240068 5.52 TRIM31 Exon  
 30184734 rs2074483 30186994 rs2284163 2.26 TRIM31 Intronic  
 30228099 rs2285797 30235302 rs9261535 7.2 TRIM10  * 30329421 rs2516723 30334283 rs4526237 4.86 HLA-L  
* 30427909 rs6905389 30429340 rs984802 1.43 RPP21  
* 30471924 rs3130113 30476614 rs3130118 4.69 HLA-E  
 31032003 rs12212418 31033964 rs11753326 1.96 DPCR1  
 31063660 rs1634731 31063908 rs2517416 0.25 MUC21  * 31101937 rs2523897 31105671 rs9262549 3.73 MUC22 
* 31110595 rs4248154 31120975 rs3131927 10.38 MUC22 3’  
* 31188411 rs2233969 31189722 rs3823402 1.31 C6orf15  
 31199971 rs3094204 31205162 rs3130558 5.19 PSORS1C1 Intron  * 31213289 rs1265100 31214247 rs3130573 0.96 PSORS1C1 Exon  
 31245144 rs3130503 31247469 rs879882 2.33 POU5F1  
 31248720 rs1265158 31251561 rs3131018 2.84 PSORS1C3 
 31314185 rs3130685 31325794 rs2894189 11.61 HLA-C  
 31435639 rs1811197 31437994 rs2523567 2.36 HLA-B  * 31538700 rs3099840 31538778 rs2596473 0.08 HCP5 5’  
* 31543970 rs2523676 31544768 rs2523674 0.8 HCP5 3’  
 31551302 rs12660382 31556133 rs2523651 4.83 HCG26  
 31557757 rs2523647 31559192 rs2516507 1.44 HCG26 3' 
 31561619 rs2516500 31567721 rs2516415 6.1 MICB 5’  
 31569068 rs3130922 31571470 rs2516408 2.4 MICB  *†  31676448 rs2857595 31680935 rs2844479 4.49 NCR3  
*† 31683255 rs9348876 31686751 rs2844477 3.5 AIF1 5' 
 31701455 rs2260000 31703466 rs2736171 2.01 PRRC2A  * 31783744 rs2242653 31786709 rs805287 2.97 LY6G6F  
 31837338 rs707938 31838993 rs707937 1.66 MSH5  
 32253685 rs2269423 32255674 rs3130349 1.99 RNF5 
 32290737 rs206015 32292323 rs404860 1.59 NOTCH4 Intron  * 32297819 rs715299 32299317 rs3830041 1.5 NOTCH4 Intron  
* 32311515 rs3130299 32315371 rs416352 3.86 NOTCH4 5’  
*† 32447054 rs2050190 32447818 rs6913309 0.76 C6orf10 Intron  
† 32473558 rs3129954 32474399 rs4248166 0.84 BTNL2 Intron  
† 32489714 rs7759742 32489917 rs743862 0.2 BTNL2 5’  
† 32497626 rs3135363 32503546 rs2187818 5.92 HLA-DRA 5’  
 32516713 rs3129878 32518115 rs3129883 1.4 HLA-DRA Intron  
 32529776 rs10947279 32536263 rs6903608 6.49 HLA-DRA 3’  
 32717405 rs9272723 32734064 rs7744001 16.66 HLA-DQA1  
 32766693 rs2858330 32767136 rs5002702 0.44 HLA-DQB1  *† 32789623 rs3916766 32791669 rs6935940 2.05 HLA-DQA2 5’  
† 32793528 rs3916765 32795336 rs3104401 1.81 HLA-DQA2 3’  
 32820225 rs9276431 32821245 rs2239800 1.02 HLA-DQA2 Exon  
 32835883 rs1023449 32839688 rs2071550 3.81 HLA-DQB2 Exon  * 32844122 rs9296044 32847866 rs1383265 3.74 HLA-DQB2 5’  
 32887974 rs5009557 32888702 rs11244 0.73 HLA-DOB  * 32905515 rs241439 32906773 rs241433 1.26 TAP2 Intron  
* 32912195 rs3819714 32913448 rs2071465 1.25 TAP2 Exon 
 32965779 rs241414 32970718 rs241407 4.94 LOC100294145 * 33007463 rs3132131 33008629 rs154972 1.17 HLA-DMB 3' 
 33010561 rs10751 33011878 rs151719 1.32 HLA-DMB 
 33013724 rs194675 33019792 rs2395296 6.07 HLA-DMB 5' *† 33072674 rs206765 33075719 rs12216336 3.05 BRD2 3' 
 33077435 rs172274 33078428 rs206762 0.99 HLA-DOA 3' 
 33080668 rs592625 33082379 rs2581 1.71 HLA-DOA  *† 33129170 rs7743563 33132251 rs435549 3.08 HLA-DPA1 3’  
† indicates intervals that reside within sperm typing segments and * indicates 
intervals that overlapped with the HapMap recombination sites. Each recombination 
site was mapped to the Human Reference Sequence Assembly 36.1 (NCBI 36.1) and 
assigned to a marker that is in the closest proximity to the site. 
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For example, the sperm typing derived recombination segment chr6: 32, 
063,170 – 32,511,466 harbored five independent recombination sites. Of the 
29 HapMap inferred recombination sites, 24 of them corresponded to the 
EHH drops and 37 of the EHH-derived recombination sites were not found in 
any of the previous studies. In addition, the examination of unambiguous HLA 
allelic SNPs haplotypes derived from trios data showed that the positions of 
LD breakage along these chromosomes coincide with the EHH-derived 
recombination sites (Figure 3.3). This high correlation of the EHH-derived 
recombination sites with the sperm typing, HapMap data and the positions LD 
breakage along haplotypes derived from the trios data illustrates the validity 
of the EHH mapping approach.  
Peaks of recombination rates were located at SNPs intervals where 
multiple haplotypes independently displayed EHH drop. For instance, a 
recombination rate peak of 4cM/Mb was located at chr6: 30,027,753 – 
30,032,404 and A*02:01, A*02:07, A*11:01 and A*24:02 haplotypes all 
exhibited EHH drop at this genomic interval. EHH-derived recombination sites 
were also found in regions with low recombination rates. These recombination 
sites were specific to a unique HLA haplotype and as such the number of 
chromosomes was not significant enough to result in elevated recombination 
rate which was estimated from population-pooled chromosomes. This 
highlights the importance of accounting for the HLA genes allelic information 
to enhance sensitivity and specificity in the inference of recombination sites 
across the MHC region. Furthermore, the HLA gene allelic EHH approach 
was able to produce excellent recombination map resolution, with 28/69 








Figure 3.3 Recombination sites derived from trios data. (A) Recombination 
sites supported by trios derived A*11:01 SNPs haplotypes. (B) 
Recombination sites supported by trios derived C*07:02-B*40:01 SNPs 
haplotypes. The arrows point to the location of EHH decay where the LD of 





Figure 3.4 EHH plots of SNP haplotypes for common HLA-A haplotypes. 
(A) CHSG, (B) CEU and (C) YRI. Dots in the panels above each plot indicate 
the SNPs interval where haplotypes break, with each color denoting a specific 
HLA-A haplotype. Positions of recombination sites and their relative sizes are 
mapped onto the plots as follows: recombination segments identified by 
sperm recombinants (highlighted in pink columns) and HapMap-inferred sites 







Figure 3.5 EHH plots of SNP haplotypes for common HLA-C-B 
haplotypes. (A) CHSG, (B) CEU and (C) YRI. Dots in the panels above each 
plot indicate the SNPs interval where haplotypes break, with each color 
denoting a specific HLA-C-B haplotype. Positions of recombination sites and 
their relative sizes are mapped onto the plots as follows: recombination 
segments identified by sperm recombinants (highlighted in pink columns) and 





3.2.3 Population-specific Recombination Sites within MHC Region 
To date, the knowledge of MHC recombination map variation across 
populations is limited and not well studied. The EHH approach integrated with 
the HLA gene allelic information offers an opportunity to perform comparative 
study of the recombination profiles between different population groups. Here, 
in addition to the CHSG population, we applied this approach to two HapMap 
populations, the Europeans (CEU) and the Nigeria Yorubans (YRI). The SNP 
genotype data of these populations were extracted from the HapMap 
depository while the HLA-A, -B and -C allelic typings were obtained from 
Erlich et al [143]. To enable comparison across the three populations, 1360 
SNPs loci whose genotypes were known in the three populations were 
selected and subjected to the EHH analysis. As HLA-DRB1 gene allelic 
information is not available for the HapMap populations, EHH analysis was 
only performed at the two genomic segments covering the HLA class I genes. 
Similar to the observation in the CHSG population, maintenance of LD 
proximate to the HLA genes were observed in the CEU as well as the YRI 
population and the range of high LD region at the HLA genes varied 
according to the underlying HLA allelic background (Figure 3.4 and 3.5).  
Collectively, there were 37 probable recombination sites detected in the 
CHSG, 30 in the CEU and 38 in the YRI (Figure 3.6). We were also able to 
recover >90% of the CHSG recombination sites identified in the previous 
section, albeit at larger segment interval. Interestingly, >50% of the identified 
sites in each population (CHSG – 56.8%, CEU – 50.0% and YRI – 63.2%) 
were uniquely population-specific. Only <16% of the sites were shared among 
the three populations and all of these sites fell within the segments 






Figure 3.6 Recombination sites across the CHSG, CEU and YRI 
population. (A) HLA-A (B) HLA-C-B. The upper section of each panel displays 
the HLA haplotypes recombination sites interval across the 3 populations. 
The lower section of each panel displays plots that indicate the number of 
unique HLA allelic haplotypes independently registered EHH drop in the 




Table 3.3 Number of common and population-specific recombination 
sites identified in the CHSG, CEU and YRI across HLA-A and –B region. Only 











In addition, recombination sites distinct to a specific population were noted to 
be in close proximity to other recombination sites unique to another 
population resulting in a boarder genomic segment where recombination 
activities are likely to occur across populations. This was especially evident in 
regions downstream of HLA-B. For instance, population-specific 
recombination sites detected in the three populations were within a 31kb 
segment (chr6: 31,089,987 – 31,120,975) downstream of MUC22 gene. This 
observation is in agreement with the previous studies where elevated 
recombination activities are likely to occur within a cluster flanked by regions 

















HLA-A 9 10 9 5 3 1 1 
HLA-B 12 5 15 1 2 3 4 
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The differences in recombination sites among populations reflect the variation 
of haplotype pool in each population. Of note, for example, A*02:01 haplotype 
can be found in both CHSG and CEU populations; however there is a 
difference in the distribution of recombination sites in A*02:01 haplotype carry 
by these 2 populations. This suggests that the differences observed in the 
distribution of recombination sites might not entirely due to the difference in 
haplotype data from each population. Hence, the consideration of HLA 
haplotypic variation within and across populations is important to improve the 
resolution of the MHC recombination map. 
 
3.2.4 Absence of Recombination in Common Asian HLA Haplotypes 
Conserved extended haplotype (CEH) is defined as a genomic segment 
with distinctive long-range sequence conservation coupled with suppression 
of recombination events [37, 38].  The presence of CEHs have been reported 
among a number of common HLA haplotypes in European (A1-C7-B8-DR3) 
[164] and Japanese populations (A24-C12-B52-DR15 and A33-C14-B44-
DR13) [165]. In our studied population, a number of four locus HLA 
haplotypes are found at relatively high frequency (>1%); notably the A*33:03-
C*03:02-B*58:01-DRB1*03:01 (A33-B58-DR3) and A*02:07-C*01:02-
B*46:01-DRB1*09:01 (A2-B46-DR9) haplotypes (Table 3.1). Next, we aim to 
investigate whether the common HLA haplotypes in the CHSG population 
would display the characteristic of CEHs. Using the phase chromosomes 
comprising of 1877 SNP markers, the major allele frequency (MAF) of the 
SNP markers was computed for each of the common CHSG HLA haplotypes. 
Contiguous SNP loci with MAF value of 1 indicates extensive conservation 






Figure 3.7 Major allele frequencies of SNP markers across the MHC 
region for common four-locus CHSG HLA haplotype. The plots were derived 
from 1877 SNP loci. Of the common Singapore Chinese HLA haplotypes, 
A33-B58-DR3 and A2-B46-DR9 displayed extensive SNPs sequence 






The MAF analysis revealed an extended region of SNPs invariant between 
HLA-F and HLA-DQB1 covering at least 3Mb for both A33-B58-DR3 and A2-
B46-DR9 HLA haplotypes; suggesting the absence of recombination events 
across the extended MHC region (Figure 3.7). In contrast, for the other four 
common HLA haplotypes, SNPs invariant was restricted only at regions 
adjacent to HLA loci and the intervening regions were characterized by the 
decay of LD. This data suggests that high frequency HLA haplotypes 
observed in a population does not necessarily imply the extended 
conservation of high LD and recombination suppression at the genomic level 
across the MHC region.  
To generate further evidence for presence of CEH in A33-B58-DR3 and 
A2-B46-DR9, DNA purified from six lymphoblastoid cell lines (B58AL, B58SC 
and B58CF HLA homozygous for A33-B58-DR3; B46BM, B46ZS and B46CM 
HLA homozygous for A2-B46-DR9) was analyzed by Illumina Human 1M-Duo 
BeadChip SNP array. After SNPs quality filtering, 10215 SNP markers were 
found in the genomic segment of chr6:25.0 – 35.0Mb; of which 7509 SNPs 
fell within the extended MHC region (28.5Mb to 33.5Mb). These SNP markers 
were then subjected to Runs Of Homozygosity (ROH) analysis, implemented 
to screen for the SNPs’ genotype homozygosity profile in each cell line. 
Regions of conservation were identified for each cell line based on levels of 
homozygosity within the genome. Homozygosity and intra-haplotype 
conservation were found not only at the HLA loci, but also across the 
extended MHC region (Figure 3.8A). For A33-B58-DR3, at least 99.5% of 
SNPs were found to be homozygous across 4.66 Mb region (Table 3.3) and 
the genotype calls of these homozygous SNPs were consistent in all the three 







Figure 3.8 Conserved extended haplotype in A33-B58-DR3 and A2-B46-
DR9 across MHC region. (A) SNPs alignment of six HLA homozygous 
individuals carrying specific haplotype. This homozygous individuals SNPs 
alignment includes the genotype status of each SNP (green vertical bars 
indicate a homozygous SNP call and dark green vertical bars indicate a 
heterozygous SNP call) and the SNP allelic call with reference to its position 
(green = adenine, red = cytosine, orange = guanine, and blue = thymine). 
10125 SNP markers are involved in the alignment (B) Identity-by-descent 
analysis. Pairwise IBD plots (IBD=1 vs IBD=0 and IBD=2 vs IBD=0) of a 
reference individual with the other respective individuals. Blue circle indicates 
pairwise analysis of individuals carrying A33-B58-DR3 while the red circle 













Table 3.4 Range of conserved extended region for the six cell lines 
derived from ROH analysis of the SNPs information. Htz: heterozygous; Hmz: 
homozygous.  











B58AL  26,922,906  33,853,071  6.93  8660  26  99.7  
B58SC  26,922,906  33,820,059  6.90  8637  26  99.7  
B58CF  28,310,997  32,973,794  4.66  6997  35  99.5  
B46BM  29,350,854  32,903,900 3.57  6238  25  99.6  
B46ZS  29,577,617  33,910,884  4.33  6975  21  99.7  












Likewise for A2-B46-DR9, the conservation region is slightly shorter at 
3.01Mb with 99.6% of the encompassing SNPs genotyped as homozygous 
(Table 3.4) and again the genotype calls of the homozygous SNPs were 
consistent in all the three A2-B46-DR9 cell lines.  To verify that the extended 
segment of conservation observed within the MHC region is not merely due to 
undetected familial relatedness among these individuals, an identity-by-
descent (IBD) analysis was performed using the whole-genome SNPs 
information of the six individuals. All the pairwise IBD analysis between every 
possible individual clustered at the bottom right quadrant (Figure 3.8B) 
indicating no strong evidence for relatedness among the individuals. 
Therefore, the SNP sequence conservation observed within the MHC region 
among individuals carrying similar HLA haplotypes is not due to familial 
relationship. These analyses reveal that for both the A33-B58-DR3 and A2-
B46-DR9 HLA haplotypes, the linkage of the HLA alleles is not restricted only 
to the HLA loci, but rather that mega-bases of genomic segment are inherited 















In this chapter, a single population cohort Singapore Chinese and their 
corresponding HLA type were used as a mean to partition the haplotypes. 
This is a great improvement over the sperm typing method which also 
recognizes the advantage of a haploid genome as a “cleaner” read-out. In 
addition, this method also counts females (which sperm typing lacks), thus 
providing a more balanced assessment of the study population. The single 
haplotype information was able to reveal unambiguously, positions along the 
MHC genome where recombination events had occurred, leading to breakage 
of SNP linkage disequilibrium and the results can thus be visualized as EHH 
plots. From the 470 chromosomes studied, we were able to identify 69 
recombination sites of which 37 recombination sites were novel. By applying 
the above approach to 2 other populations, European and African, we were 
able to show that each population has its own unique signature of 
recombination sites within the MHC. This has not been empirically defined till 
now and even more interesting is that the population-specific recombination 
sites are seldom shared (or seen) among the 3 populations studied; 
highlighting the role of recombination in generating haplotype diversity. 
Through this study, for the first time, we revealed two HLA haplotypes in the 
Singaporean Chinese population (A2-B46-DR9 and A33-B58-DR3) with little 














Intra-haplotypic Variation in MHC 




















Typically, the linkage disequilibrium (LD) breakdown becomes evident 
over certain regions along the MHC with the extent and arrangements 
markedly defined by the HLA alleles. However, in the previous chapter, we 
revealed extensive LD lacking any recombination events covering a region of 
at least 4.66 Mb in individuals carrying A33-B58-DR3 and 3.01Mb in A2-B46-
DR9. CEHs draw great interests not just because of their unique genomic 
traits but also because common conserved extended haplotypes (CEHs) are 
known to be associated with numerous diseases [35, 166]. For instance, the 
A1-B8-DR3-DQ2 haplotype alone is a risk factor for type 1 diabetes, systemic 
lupus erythematosus, rheumatoid arthritis and IgA deficiency and various 
other diseases [40-42]. Of note, studies have consistently demonstrated the 
association of A33-C3-B58-DR3 and A2-C1-B46-DR9 common HLA 
haplotypes with nasopharyngeal carcinoma [167, 168], myasthenia gravis 
[169] and type 1 diabetes [170]. Despite the strength of the risk associations, 
genetic dissections of the exact disease-causing variants and genes have 
been difficult. Firstly, due to the long and extensive LD on these CEHs, it is 
often difficult to distinguish between disease-causing variants and other 
benign variants in linkage within the same haplotype, causing difficulty in 
identifying the genes or variations responsible for causing disease. Secondly, 
the extent of intra-haplotypic variation within the conserved region of the 
CEHs, which might separate disease-affected haplotype carriers from 
unaffected haplotype carriers, is not well-established. Previous attempts to 
decipher the difference between type-1A diabetic A1-B8-DR3-DQ2 
haplotypes and non-type-1A diabetic A1-B8-DR3-DQ2 yielded uninformative 
results, despite the high resolution of the common SNPs (MAF>=5%) 
genotyping platform [164]. Such attempts may be futile because they did not 
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include intra-haplotypic variants that might be rare at the population level. 
Indeed, studies have shown that functional variants whose frequency were 
too low to be detected by genome-wide association exhibit significant disease 
susceptibility effects [171, 172]. Thus, further efforts are needed to 
characterize both the extent of LD and the extent of intra-haplotypic variation 
within CEHs. 
Attempts to quantify the level of polymorphism within MHC haplotypes 
haven been carried out on eight European MHC haplotypes using bacterial 
artificial chromosome cloning (BACs) and shotgun sequencing [14, 15]. 
Among these cells, only the MHC haplotype of PGF (A3-B7-DR15-DQ6), and 
COX (A1-B8-DR3-DQ2), were sequenced completely and the MHC reference 
sequence of PGF was incorporated into the mosaic NCBI Build 37.2 
reference sequence [16]. Each of these haplotypes was assembled into a 
haploid sequence from a single consanguineous cell line using BAC derived 
sequences; however, as the parental origin of each BAC sequence was 
uncertain and with only one representative from a particular HLA haplotype, 
there is no information on intra-haplotypic variation, hence the characteristic 
features of these haplotypes cannot be determined. Smith and colleagues 
went a step further, using PCR primer pairs, covering the MHC region, to 
perform partial re-sequencing for 19 independent A1-B8-DR3-DQ2 
chromosomes and in the process identified only 11 single-nucleotide variants 
(SNVs) between HLA-A and HLA-DQ gene [21].  Unfortunately, in this study 
only 15% of the conserved region was sequenced, and it was thus unable to 
definitively explore the scope of variation in the CEHs. Subsequent studies 
employed target region and next generation re-sequencing approaches to 
interrogate variations residing within the MHC region [19, 20] but cell lines 
were either HLA heterozygous or did not exhibit CEH characteristics in the 
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MHC genomic region and as a result, haplotype sequence assignment was 
problematic. The sequences of the eight common European MHC haplotypes 
and the variations characterized from the analysis of these sequences were 
often used as a framework and resource for MHC disease susceptibility 
studies. Though useful, given the immense diversity of the MHC region, these 
are not sufficient to provide a complete description of the region in particularly 
for individuals from other ethnic backgrounds. 
In this study, we report the characterization of two Asian CEHs, A*33:03-
C*03:02-B*58:01-DRB1*03:01 (A33-B58-DR3) and A*02:07-C*01:02-
B*46:01-DRB1*09:01 (A2-B46-DR9) which are present in relatively high 
frequencies of about 7% and 6% respectively in the Singapore Chinese 
population who are predominantly descended from Southern China [173, 174] 
. In contrast to earlier studies which examined only one representative of a 
particular MHC haplotype, we compared 3 unrelated individuals for each CEH 
and subjected them to whole genome sequencing. The data will provide an 
in-depth, nucleotide-resolution view of these prominent Asian CEHs, and 











4.2.1 Fine-scale Mapping of A33-B58-DR3 and A2-B46-DR9 CEHs using 
Deep-sequencing 
The use of high density SNP typing at 1 SNP per 665 bp as described in 
the previous chapter demonstrated that conserved extended haplotypes of 
HLA identical independent individuals appeared to be indistinguishable. It is 
as yet not known if this conservation is maintained at the nucleotide level. To 
do so, six HLA homozygous cell lines B58AL, B58SC, B58CF, B46BM, 
B46ZS and B46CM were subjected to whole-genome sequencing (WGS) 
using the Complete Genomics (CG) platform.  Raw reads were processed by 
the Complete Genomics Standard Sequencing Pipeline 2.0, and assembled 
according to the Genome Reference Consortium Human genome build 37 
(GRCh37) [150]. For each sequenced genome, the mean coverage per base 
pairs was at least 37.13 times covering no less than 94.18% of the extended 
MHC region (28.5Mb to 33.5Mb) (Table 4.1). Nearly half of the uncovered 
base pairs were within the 32,435,000 – 32,660,000 segment encompassing 
the HLA-DRB, HLA-DQA1, HLA-DQB1, pseudogenes and 43.66% - 60.42% 
of this 225kb region was not covered (Figure 4.1). This low rate of sequence 
calling is likely due to the highly polymorphic nature of the HLA-DRB region 
where multiple insertions and deletions of large genomic sequence result in 
haplotype-specific rearrangements of the HLA-DRB genes and its 
pesudogenes, making the alignment of this segment particularly difficult. 
Hence, the HLA-DRB region, together with another region between 
31,210,000-31,235,000 where low coverage was observed due the repetitive 












Table 4.1 CG sequencing coverage and performance. The mean 
coverage is at least 37.13 per cell line, resulting in high confidence calls for at 














% of MHC 
region 
covered  
B58AL 44.67 98.14 91.09 61.40 95.31 
B58SC 43.69 98.10 90.57 59.44 95.15 
B58CF 39.06 97.96 88.14 49.10 94.66 
B46BM 43.54 98.13 90.31 58.93 95.03 
B46ZS 44.30 98.11 90.88 60.94 95.06 
B46CM 37.13 97.86 86.64 44.20 94.18 
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Figure 4.1 No-call and coverage profile for each cell line across the MHC 
region. The average GC corrected coverage and the no-call counts were 
binned into non-overlapping 20kb windows. Low coverage and high no-call 
rate were predominantly located at the HLA-DR region. 
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To assess the quality of data generated from the CG platform, genotypes 
calls between 25Mb to 35Mb from the Illumina Human 1M-Duo BeadChip 
SNP array were compared with the deep sequencing data. The results 
showed a high concordance rate of 99.5% for A33-B58-DR3 and 99.6% for 
A2-B46-DR9 between SNPs genotyping and the CG data (Table 4.2). 48 call 
sites among the discordant data were randomly selected for validation by 
PCR re-sequencing.  Of these, 45/48 were found to be consistent with the CG 
data, while only 3/48 agreed with the SNP genotyping array data (Table 4.3), 
indicating that the CG sequencing platform in general delivers higher call 
accuracy than the SNP genotyping platform. 
Next, the range of genomic conservation in each sample was assessed 
using homozygosity levels in the deep sequencing data. Nucleotides within 
the 25Mb -35Mb region of chromosome 6 were binned into windows of 5kb, 
and the numbers of homozygous and heterozygous reference single 
nucleotide variants (SNV) calls within each bin were examined. Stretches of 
homozygosity were defined to be regions with no more than four consecutive 
windows having the zygosity SNVs ratio (number of homozygous SNVs 
against total number of SNV in a given window) of less than 0.95. The 
resulting conservation region in each genome coincided with the region 
determined using the SNPs genotyping platform (Table 4.4) and regions 
outside the conserved segments have comparably much higher number of 












Table 4.2 SNP genotype call differences between Illumina Human 1M-
Duo BeadChip and CG sequencing. Hmz indicates homozygous genotype 
call and htz indicates heterozygous genotype call. 













B58AL  9916  15  1  23  39  99.6  
B58SC  9876  14  4  26  44  99.6  
B58CF  9880  12  8  27  47  99.5  
B46BM  9908  11  8  14  33  99.7  
B46ZS  9903  13  3  14  30  99.7  











Table 4.3 Re-sequencing experiments to assess mismatches between 
SNP genotyping and CG sequencing platform in samples carrying A33-B58-
DR3 and A2-B46-DR9 haplotype. 45/48 of the positions assessed were in 
agreement with the CG data. 
A33-B58-DR3 
Position rsID  Ref  
B58AL B58SC B58CF 
SNP 
Array CG PCR 
SNP 
Array CG PCR 
SNP 
Array CG PCR 
29,796,376 rs12722477 C C/C A/A ?/? C/C A/A A/A C/C A/A A/A 
29,819,909 rs2508053 C C/T C/C C/C C/T C/C C/C C/T C/C C/C 
30,383,046 GA005234 C C/G C/C C/C C/G C/C C/C C/G C/C C/C 
30,418,354 rs34111681 G T/T G/G G/G T/T G/G G/G T/T G/G G/G 
31,170,514 rs9263870 A A/G G/G G/G A/G G/G G/G A/G G/G G/G 
31,321,327 rs9266095 A A/G A/A A/A A/G A/A A/A T/T G/G ?/? 
31,639,979 rs9267532 C C/T T/T T/T C/T T/T T/T C/T T/T T/T 
31,655,438 rs10573 G A/G A/A A/A A/G A/A A/A A/G A/A A/A 
31,697,558 rs707916 G A/G A/A ?/? A/G A/A ?/? A/G A/A A/A 
32,130,937 rs10680 T C/C T/T T/T C/C T/T T/T C/C T/T ?/? 
33,036,549 rs17509489 T G/G T/T ?/? G/G T/T T/T G/G T/T ?/? 
            
A2-B46-DR9 
Position rsID  Ref 
B46BM B46ZS B46CM 
SNP 
Array CG PCR 
SNP 
Array CG PCR 
SNP 
Array CG PCR 
29,801,958 rs2743944 T T/C T/T T/C T/C T/T T/C T/C T/T T/C 
29,913,509 rs1062405 T C/C T/T T/T C/C T/T T/T C/C T/T T/T 
29,942,191 rs2232236 T G/G del/del del/del G/G del/del ?/? G/G del/del del/del 
30,704,985 rs28380598 T C/C T/T T/T C/C T/T T/T C/C T/T T/T 
31,079,236 rs1265055 G A/G A/A A/A A/G A/A A/A A/G A/A A/A 
31,082,304 rs3130554 T G/T T/T T/T G/T T/T T/T G/T T/T T/T 
32,130,937 rs10680 T C/C T/T T/T C/C T/T T/T C/C T/T ?/? 
33,036,549 rs17509489 T G/G C/T C/T G/G T/T T/T G/G T/T T/T 
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 Figure 4.2 Zygosity profile of variants derived from deep sequencing. The 
region chr6: 25Mb – 35Mb was binned into non-overlapping windows of 20kb. 
The number of homozygous (hmz) and heterozygous (htz) variants with 
respect to the NCBI Build 37.2 reference sequence was calculated in each 
bin. For each of the six individuals, the upper panel plot represents the 
homozygous variants counts while the lower panel plot represents the 










Table 4.4 Range of conserved extended region for the six cell lines 
derived from CG data. 
Cell line Start End 
Length 
(Mb) 
No. of htz 
variants  
B58AL  26,630,000 33,830,000 7.48 595 
B58SC  26,350,000 33,810,000 7.46 578 
B58CF  28,350,000 32,950,000 4.60 455 
B46BM  29,367,500 32,917,500 3.55 221 
B46ZS  29,630,000 33,890,000 4.26 146 











CG data showed at least 99.99% homozygosity in all samples, with the A33-
B58-DR3 haplotypes samples having on average 8.33 heterozygous calls per 
100kb, while the A2-B46-DR9 haplotypes samples having on average 4.89 
heterozygous calls per 100kb. Large numbers of homozygous reference 
variant calls were observed within or proximate to the HLA genes, highlighting 
the difference in the HLA allelic combination between the reference genome 
and our samples. Despite the extensive number homozygous reference 
variants, small pockets of heterozygous variants randomly spread across the 
conserved MHC region were observed. Of interest, spike of heterozygosity 
centromeric of the HLA-A gene was detected in the A33-B58-DR3 samples 
even though high density SNP profiling have indicated high level of 
homozygosity in this genomic region. This characteristic has not been 
observed in the previous studies of CEH as the high density SNPs 
geneotyping platform is not able to provide the necessary resolution. 
 
4.2.2 Intra-haplotypic Conservation and Variation 
The use of three HLA homozygous diploid samples of each Asian CEH 
offered the opportunity to characterize the extent of intra-haplotypic variation 
and conservation. Using the CG platform, the three diploid samples of each 
haplotype yielded 6 haploid sequences, which were compared to each other 
at each nucleotide position across the length of the sample with the shortest 
range of homozygosity. The range compared for A33-B58-DR3 was 
chr6:28,350,000-32,950,000, and the range compared for A2-B46-DR9 was 
chr6:29,630,000-32,650,000. Nucleotide positions having ambiguous or low 
confidence score in two or more haploid would be regarded as no-called (“N”) 
in the consensus sequence. Accounting for the gaps within the region, we 
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were able to establish 4,135,945 bp of phase-discrete sequence 
representative of the A33-B58-DR3 haplotype and 2,720,646 bp of phase-
discrete sequence representative of the A2-B46-DR9 haplotype. Next, the 
number of positions with SNVs and insertions/deletions (indels) between the 
six sequences were computed, and plotted against chromosome position 
(Figure 4.3). Within the conserved region, the degree of intra-haplotype 
variation was found be exceptionally low; 293 SNVs and 52 indels were 
identified in the A33-B58-DR3 haplotype, while 238 SNVs and 51 indels were 
observed in A2-B46-DR9 haplotype. A closer inspection revealed that 
majority of the intra-haplotypic variations in each MHC haplotype was 
localized to a single region. For example, spikes of variation localized to a 
120kb region covering the ZFP57 and HLA-F gene (chr6:29,600,360 – 
29,721,396) were found in the A2-B46-DR9 haplotype but not in A33-B58-
DR3 haplotype (Figure 4.4A) and these variations make up >70% (171/238) 
of the total A2-B46-DR9 intra-haplotyic SNVs. Similarly, elevated number of 
A33-B58-DR3 intra-haplotypic variations accounting for 90% (262/293) of 
SNVs were observed at a 240kb region covering the HLA-A gene (chr6: 
29,733,502 – 29,971,973) while the number of intra-haplotypic variation in the 
A2-B46-BR9 in this region was distinctly lesser (Figure 4.4B). The estimated 
nucleotide diversity value (π) between the A33-B58-DR3 haploid sequences 
and A2-B46-DR9 haploid sequences was 7.08 X 10-5 and 8.75 X 10-5 
respectively. In comparison, these values are 38- to 48-fold lower than the 
nucleotide diversity found between PGF and COX (3.4 X 10-3) [15], the two 
common MHC haplotype found in the European population and at least 5-fold 
lower than the nucleotide diversity between any two haplotypes across the 
human genome [175, 176]; indicative of extreme low nucleotide diversity in 









Figure 4.3 Distribution of intra-haplotypic variations across the MHC 
region. Each data point on the plot represents the number of SNV counts 
(red) and the number of indel counts (blue) in a non-overlapping 5kb window. 
The number of variations for each haplotype was derived from the 
comparisons of six haploid chromosomes at every possible nucleotide 
position across the MHC region. The pink bars indicated regions where the 







Figure 4.4 Spikes in Intra-haplotypic variations found in (A) A2-B46-DR9 
haplotype and (B) A33-B58-DR3 haplotype. The variation counts were binned 
into non-overlapping 2kb windows. Heighten intra-haplotypic variation 
genomic segments extended up to 120kb and 240kb were identified in the 




Outside the boundaries of conserved region, the number of variations 
between the haploid sequences was significantly increased. 
Using NCBI RefSeq Build 37.2 gene annotation, intra-haplotypic 
variations were grouped into functional categories (Table 4.5) with the 
majority of the variants (~80%) resided in the non-coding region, while less 
than 1.5% of all variants were located in the exonic region (Figure 4.5). 
Coding region variants showed equal proportion of missense and 
synonymous mutations (Table 4.6). Surprisingly, missense mutations were 
found in A33-B58-DR3 haplotype samples, on exon 7 of HLA-A and exon 1 of 
HLA–B. To validate these variants, the HLA-A exon 7 (position 29,913,037) 
missense variant was cloned and re-sequenced. The results confirmed its 
presence in all three samples of A33-B58-DR3 (Figure 4.6, Figure 4.7 and 
Figure 4.8) and within this 479 bp cloned fragment, 13 heterozygous and 15 
homozygous variants were in agreement with the CG data (Table 4.7). Using 
in-silico tools to predict the possible functional effect of these missense 
mutations [177, 178], it was found that the induced amino acid substitutions 
would have minimal effect on the protein function (Table 4.6). In total, 77 
novel SNV variants were identified within the A33-B58-DR3 samples, and 50 
novel SNV variants within the A2-B46-DR9 samples that were not annotated 
in dbSNP build 132, the 1000 Genome Project and the International HapMap 
Project (Table 4.8 and Table 4.9). The discovery of these novel SNPs 












Figure 4.5 Functional annotation of variants for each haplotype based on 
NCBI gene annotation Build 37.2. It was noted majority of the variants were 
found in the non-coding region while only less than 1.5% were found in the 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.3 Intra-haplotypic Variations in A2-B46-DR9 Influence the 
Expression of ZFP57 
Although the intra-haplotypic variants appear to be highly homologous, 
single nucleotide differences may exert functional consequences. To illustrate 
this mechanism, SNP rs29228 (chr6: 29,623,739) has been found to exert a 
cis-acting effect on the expression level of the Zinc Finger Protein 57 homolog 
(ZFP57) [179], located 16.43kb centromeric to rs29228. It was reported that 
carriers of the “AA” but not the “GG” genotype of rs29228 would support 
expression of ZFP57. Such locus where genetic variation is associated with 
the gene expression variation is commonly known as expression quantitative 
trait loci (eQTL) SNP [129]. A more recent study revealed four additional 
eQTL SNPs (chr6:29,644,502 – rs375984, chr6:29,647,628 – rs416568, 
chr6:29,648,398 – rs365052 and chr6:29,648,564 – rs2747431), located in 
the ZFP57 introns and promoter region, were associated with the expression 
of ZFP57 [180]. Interestingly, these SNP positions are intra-haplotypic 
variants in A2-B46-DR9 but not for A33-B58-DR3 haplotype. To learn whether 
the difference in nucleotide at these positions would affect the expression of 
ZFP57, reverse transcription quantitative PCR was performed to evaluate the 
ZFP57 mRNA levels in B58AL, B58SC, B58CF, B46BM, B46ZS, B46CM as 
well as the two European cell line COX and QBL. Noticeably, the COX, 
B46BM and B46CM cell line possess the “A” allele at chr6: 29,623,739, “T” 
allele at chr6: 29,644,502, “A” allele at chr6:29,647,628, “C” allele at 
chr6:29,648,398 and “T” allele at chr6:29,648,564 exhibited evidence of 
ZFP57 expression while B46ZS, possessing the alternate allele at these 













Figure 4.9 Association of A2-B46-DR9 intra-haplotypic variants with 
ZFP57 expression. RT-qPCR was performed to determine the mRNA level of 
ZFP57 in two biological replicates of COX, QBL, B46BM, B46ZS, B46CM, 
B58AL, B58SC and B58CF cell lines. Experiments were carried out in 
triplicates for each of the biological replicate. Triangle symbol indicates 
quantitative expression derived from biological replicate 1 while square 











Similarly, no ZFP57 expression was observed in the A33-B58-DR3 and QBL 
cell lines that possess the alternate alleles. This result highlights the 
possibility that intra haplotypic variants would have an effect on the 
expression of genes within the MHC region among individuals carrying 
identical MHC CEHs. 
The presence of eQTL SNPs associated with ZFP57 indicates possible 
regulatory role for polymorphic sites in the genomic region proximate to these 
eQTL SNPs. To identify putative regulatory variants to ZFP57, we examined 
the intra-haplotype sequence variations in the A2-B46-DR9 cell lines in the 
90kb genomic region (chr6:29,600,000 – 29,690,000) encompassing the 
ZFP57 gene. A total of 202 A2-B46-DR9 intra-haplotypic SNVs were found 
within the genomic segment of interest and the majority of these variants 
were localised centromeric of the ZFP57 (Figure 4.10). Interestingly, the 
nucleotide call of the 170 variants in the B46ZS cell line matched with the 
three cell lines carrying the A33-B58-DR3 haplotypes, suggesting these sites 
as potential regulatory variant candidates. Next, we determined the epigenetic 
landscape of this 90kb genomic region using the histone modifications data in 
BLCL obtained from the ENCODE project [181]. Sequences bearing 
H3K27ac, H3K4Me1, H3K4Me3 marks and DNase I hypersensitivity sites are 
reported to indicate the presence of enhancers and transcriptional activities 
[182-184].  Our analysis of the histone marks showed two elevated peaks of 
histone modification overlapped with a cluster of 25 intra-haplotypic variants 
at the intron 1 or promoter region of ZFP57 (chr6: 29,645,000 – 29,650,000) 
(Figure 4.10).  This provides suggestive evidence that polymorphic sites in 









Figure 4.10 Mapping of putative regulatory variants for ZFP57. Epigenetic 
landscape in the 90kb genomic region. Histone modifications data from the 
ENCODE project based on the profiling of B-LCL (GM12878) were accessed 
through the UCSC Genome Browser (http://genome.ucsc.edu/). The lower 
panel represents the intron 1 or promoter region of ZFP57. Through in-silico 








In-silico transcription factors binding sites prediction using Physbinder [185] 
revealed 10/25 of the polymorphic sites were potential binding sequence for 
transcription factors such as GATA1, GATA2, IRF3, NFYA, ETS1 and BRCA1 
(Figure 4.10) and sites with no predicted transcription factors binding were 
mostly located at the region between the two histone modification peaks. 
These highlight that the 10 sites of intra-haplotypic variant have potential 
binding affinity to transcription factors. 
 
4.2.4 Inter-haplotype Evaluation Reveals Non-random Genetic 
Variation across MHC Region 
Next, the A33-B58-DR3 and A2-B46-DR9 CEH were compared against 
eight haplotypes of European origin: PGF, COX, QBL, APD, DBB, MANN, 
MCF and SSTO [14] to examine the degree of sequence variation or 
similarity. The derived consensus haploid sequences for the A33-B58-DR3 
and A2-B46-DR9 haplotypes were aligned pairwise with each of the eight 
European MHC haploid data. For each pairwise comparison, sequence gaps 
and positions of no-calls in either haplotype compared were excluded, we 
observed distinct regions of increased variation at chromosomal regions 
around HLA-A (29.6-30.0Mb) and HLA-C – HLA-B (31.25-31.5Mb) (Figure 
4.11). Since the various haplotypes compared have different HLA-A, -B and -
C alleles, divergence detected at these loci are expected. In addition, even 
though the HLA loci alone are less than 12kb in length and the peaks of 








Figure 4.11 Pairwise inter-haplotypic variations across MHC region. A33-
B58-DR3 and A2-B46-DR9 haplotype sequence were compared with each of 
the eight common European-descent MHC haplotype (PGF, COX, QBL, DBB, 
SSTO, MCF, MANN, APD). The variation counts were binned into non-
overlapping 5kb windows. The red bars indicate gaps in the sequence of the 
European MHC haplotypes. Elevated sequence variation between haplotypes 





It has been reported that the flanking regions of the HLA genes extending up 
to thousands of kilobases can still be strongly linked with the associated HLA 
alleles [163, 174], and thus explains the extended increased in variation 
surrounding the HLA genes between haplotypes. We also performed 
functional characterization of the variants between haplotypes specifically the 
comparison of the 2 Asian CEH haplotypes with PGF and COX. 
Unsurprisingly, the number of inter-haplotype variation was significantly 
higher than the number of intra-haplotype variation (Table 4.6). Likewise, 
there was an elevated percentage (~2.2%) of inter-haplotype variation 
occurred in the gene coding region. The estimated π between the Asian 
haplotypes was 2.70 X 10-3, and between the Asian and the European 
haplotypes the π values range from 2.11 X10-3 to 2.55 X 10-3. These values 
indicate that the MHC region sequence differences between the Asian 
haplotypes are not significantly greater or lesser than between Asian and 
European. 
To examine the patterns of inter-haplotype variation, we binned the 28.35-
32.95Mb into windows of length 5kb, and a frequency histogram of the 
number of variations for each window was plotted (Figure 4.12A).The 
distribution observed was skewed left, with most windows had relatively low 
amounts of variation, albeit a few windows had extremely large amounts of 
variation. There is no window that had less than 1 variant, indicating that 
there is no large region of complete conservation across haplotypes within the 
extended MHC region. Figure 4.12B shows the range of the number of 
variations for each 10-percentile block. The top 10% of windows with the most 
number of variants have between 28-109 variants each, which are 5-20 times 
the MHC region-wide average of 5.39, implying that variation between the 
haplotypes across the MHC region is generally constant except in regions 
surrounding the HLA genes. Next, we identified regions of length >30kb with 
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all windows containing below 3 variants or above 15 variants (Table 4.10) to 
mark out regions of low and high variation respectively.  
Surprisingly, a cluster of low-variation regions was observed surrounding 
the RCCX region, which included the C2 and RAGE loci.  This may indicate 
conservation of these essential components of the innate immune system.  
The regions containing the highest amounts of variation were, as expected, 
the class I and class II loci and their neighboring regions.  The amount of 
variation in these regions is remarkable, with on average 8 times the amount 























Table 4.10 Regions of low and high variation between the 
sequenced MHC haplotypes 






/5kb  Genes 
28,350,000 28,415,000 65 0.61 ZSCAN12, ZSCAN23 
28,430,000 28,495,000 65 1.96 GPX6 
28,560,000 28,670,000 110 0.78 Downstream SCAND3, Upstream LOC401242 
29,545,000 29,630,000 85 1.47 SNORD32B, OR2H2, GABBR1 
30,545,000 30,680,000 135 1.49 PPP1R10, MRPS18B, ATAT1, C6orf136, DHX16, PPP1R18, NRM 
31,690,000 31,805,000 115 1.66 
DDAH2, CLIC1, MSH5, SAPCD1, 
VWA7, VARS, LSM2, HSPA1L, 
HSPA1A, HSPA1B 
31,845,000 31,895,000 50 1.90  EHMT2, C2, ZBTB12 
31,905,000 31,965,000 60 1.39 C2, CFB, NELFE, SKIV2L, DOM3Z, STK19, C4A, C4B 
31,980,000 32,160,000 180 1.84 
CYP21A2, TNXB, ATF6B, FKBPL, 
PRRT1, LOC100507547, PPT2, 
EGFL8, AGPAT1, RNF5, AGER,PBX2 
32,855,000 32,895,000 40 1.35 LOC100294145 
     






/5kb  Genes 
29,665,000 29,715,000 50 16.16 HLA-F 
29,730,000 29,805,000 75 26.54 HCG4, LOC554223, HLA-G 
29,820,000 29,975,000 155 36.93 HLA-H, HCG4B, HLA-A, HCG9 
31,005,000 31,105,000 100 19.59 HCG22, C6orf15, PSORS1C1, CDSN 
31,155,000 31,360,000 205 45.62 HCG27, HLA-C, HLA-B 
31,375,000 31,415,000 40 22.38 MICA 
32,190,000 32,220,000 30 18.97 Downstream NOTCH4 














Figure 4.12 Distribution of inter-haplotypic variation. (A) Frequency 
histogram of the number of variations for each 5kb window. (B) Cumulative 













The RCCX region within chr6:31,939,646-32,077,151 is a common multi-
allelic copy number variation locus.  The number of modules and type of C4 
complement genes within the RCCX region vary between individuals and the 
gene dosage of C4A and C4B have been associated with various disorders.  
For instance, lower levels of C4A have been associated with susceptibility for 
systemic lupus erythematosis [186], while lower levels of C4B have been 
associated with increased rates of acute myocardial infection and stroke 
[187]. To identify the number and type of RCCX modules associated with 
each of our haplotypes, we interrogated the RCCX region of each sample 
using a SYBR Green real-time PCR assay with primers specific for C4A, C4B, 
C4L, C4S, TNXA, and RP1.  The total number of modules can be determined 
by three separate counts: (C4A + C4B)/2, (C4L + C4S)/2, and (TNXA + 2)/2.   
In all samples, these counts gave a consistent total number of modules, 
thus showing internal validation of results. The A33-B58-DR3 haplotype was 
found to be monomodular, with one copy of C4A which was long.  The A2-
B46-DR9 haplotype was found to be bimodular, with 1 copy of C4A and 1 
copy of C4B, one of which was long, and the other short (Table 4.11).  We 
also report that APD, whose RCCX modular configuration is previously not 


















Table 4.11 RCCX modular structure in the 6 Singaporean Chinese cell 
lines and the APD cell line (European origin). The number of modules in each 
cell line was determined by the following counts: (C4A + C4B)/2 or (C4L + 
C4S)/2 or (TNXA + 2)/2. These 3 independent counts served as an internal 
verification for the number of RCCX modules carried by each cell line. 
RCCX Structure Sample C4A C4B C4L C4S TNXA 
Monomodular  
B58SC 2 0 2 0 0 
B58AL 2 0 2 0 0 
B58CF 2 0 2 0 0 
Bimodular  
B46BM 2 2 2 2 2 
B46ZS 2 2 2 2 2 
B46CM 2 2 2 2 2 










4.2.5 Conservation of HLA-DR Region between Asian and European 
Haplotypes 
The availability of the Asian MHC haplotype sequences together with the 
sequences of the eight European haplotypes offers an excellent opportunity 
to study the MHC haplotypic relationship and provides insights into their 
recent evolutionary history. To do this, phylogenetic trees were derived from 
the SNP sequences of the MHC haplotypes and a total of four phylogenetic 
trees were built; representing the extended MHC region (29.65-33.0Mb), 
HLA-A region (27.0-30.2Mb), HLA-B region (31.1-31.6Mb) and HLA-DRB1 
region (32.3-32.8Mb) (Figure 4.13A-D). The analysis showed that the trees 
were typically split into two main branches and the branching was not 
determined by the population ethnicity. In fact, the two Asian haplotypes 
were never found to form sister nodes with each other; instead, each 
Asian haplotype could be consistently found associating under the 
same clade with specific European haplotypes.  For instance, the A33-
B58-DR3 haplotype cell lines were found to be more closely related with the 
COX and QBL European haplotype at the HLA-DRB1 region than with the A2-
B46-DR9 haplotype. This close relation of the Asian A33-B58-DR3 haplotype 
with COX and QBL is likely because these haplotypes carry the same HLA-
DRB1*03:01 allele; the phylogenetic tree at the HLA-A and HLA-B region did 
not show such close association between the haplotypes. Likewise, the A2-
B46-DR9 haplotype is more closely related to the DBB and MCF European 
haplotypes and this association is due to common possession of the HLA-A2 
subtype allele. These analyses imply that the MHC haplotypic association is 







Figure 4.13 Phylogenetic relationships between Asian MHC haplotypes 
and European MHC haplotypes. Maximum likelihood (ML) tree derived from 
SNP sequence of the MHC haplotypes covering the (A) chr6:29.65 – 
33.00Mb segment (18,781 SNPs), (B) chr6:29.70 – 30.20Mb segment (5,111 
SNPs), (C) chr6:31.10 – 31.60Mb segment (3,617 SNPs) and (D) chr6:29.70 
– 30.20Mb segment (5,237 SNPs). The bootstrap value for each branch is 
indicated at the branching point. Generally most branches were able to 
achieve bootstrap values of >75 suggesting the reliability of the phylogenetic 






The COX and QBL cell lines were previously reported to have almost 
identical genomic sequences covering the HLA-DRB1, -DQA1 and DQB1 
genes [15], and the phylogenetic analysis has demonstrated the close 
relationship between these haplotypes with the Asian A33-B58-DR3. To 
investigate the sequence relationship between the Asian and European 
genomes, we extracted 4441 consecutive SNPs derived from CG sequencing 
for the three cell lines carrying HLA-DRB1*03:01 allele; and compared with 
the COX and QBL nucleotide profiles. Given that the sequence length and 
genes composition are not entirely similar between the Human Reference 
Sequence Assembly 37.2 and the European haplotypes at the HLA-DR 
region, for this analysis, the COX sequence and genes annotation was used 
as reference. The selected 4441 SNPs spanned over 402,427bp of the COX 
sequence, encompassing the HLA-DRA, -DRB1, -DQB1, -DQA2, -DQB2 and 
-DOB genes. From the comparison, indeed, a 160kb segment enclosing the 
HLA-DR genes of the A33-B58-DR3 haplotype was almost identical to COX 
and QBL (Figure 4.14). Of the 1508 SNPs that fall within this 160kb segment, 
1506 SNPs have nucleotide profiles that matched with COX and QBL, 
illustrating a remarkable conservation at the HLA-DR region among these 
haplotypes. The immediate centromeric end of this segment corresponds to a 
recombination hotspot providing strong evidence for haplotype break-up. 
Interestingly, the conservation region range between A33-B58-DR3 cell lines 
and QBL was even longer, extending up to almost 300kb. A smaller genomic 
segment of 58kb containing the HLA-DOB was detected to be almost identical 
to COX but not QBL. Again, this 58kb segment is flanked by recombination 
hotspots at both its telomeric and centromeric ends. These extreme 
conservations between the Asian and European haplotypes point to a shared 














Figure 4.14 A33-B58-DR3 SNPs comparison with COX and QBL in the 
HLA-DRB region. COX sequence assembly and gene annotation 
(HSCHR6_MHC_COX_CTG1) was used as the reference for the comparison. 
The 4441 SNPs of B58AL, B58SC and B58CF, spanning over 402,427bp of 
the COX sequence, were included in this comparison.  Dark blue bars 
indicate shared segment found in all samples while the light blue columns 





















In this study, with the use of HLA homozygous cell lines, we 
demonstrated extensive sequence conservation in two common MHC 
haplotypes of Asian ancestry - A33-B58-DR3 and A2-B46-DR9 by high 
throughput genome sequencing. We also for the first time described the 
extent of intra-haplotypic variation within the conserved boundaries of the 
MHC CEHs and revealed haplotype-specific novel variations. More 
significantly, we demonstrated that intra-haplotypic sequence variation in the 
cell lines carrying A2-B46-DR9 haplotype are associated with the expression 
of ZFP57; suggesting possible functional role in some of these polymorphic 
sites. Another major finding is that extreme sequence conservation extending 
up to 160kb at the HLA-DR region was found between the Asian A33-B58-
DR3 haplotype and the European haplotypes (COX:A1-B8-DR3; QBL:A26-
B18-DR3); implying individuals carrying these haplotypes shared a common 
ancestor. Overall, this approach has allowed us to assemble at least 90% 
phase-resolved MHC sequence representative of the A33-B58-DR3 and A2-
B46-DR9 haplotype. The availability of these alternate Asian MHC sequences 
would complement the eight European MHC haplotype sequenced by the 

















Transcriptome Landscape in MHC 















Gene expression profile plays an important role in defining the phenotypic 
status in complex diseases. Description on gene transcripts, transcripts 
variability and isoform structure can provide insights on how differential gene 
expression leads to functional alteration that define phenotypic status. The 
MHC genomic region of approximate 4Mb has been associated with more 
than 100 diseases, including cancers, autoimmune diseases, infectious 
disease susceptibilities, neurodegenerative, cardiovascular, and metabolic 
disorders [6, 7]. Furthermore, many of these genetic associations are 
implicated by specific HLA haplotype marked by extensive LD most notably 
found in the common CEHs [13]. The ability to study the MHC transcription 
profile at haplotypic resolution can yield better understanding of the effects of 
HLA haplotypic differences on gene expression. 
Currently, transcriptome characterization for the human MHC at 
haplotypic resolution has proven to be complicated. Firstly, the probes in the 
standard commercial expression microarray are annotated to the human 
genome reference sequence, thus are unable to account for the population 
MHC sequence and haplotype variation. The consequence of this is that 
individuals with different HLA haplotypic background and sequence profile 
from the reference sequence may not display expression of certain genes 
because the probes are unable to anneal to their unique gene sequences 
[188, 189]. This could distort the evaluation of gene expression and lead to 
erroneous conclusions. Secondly, majority of the individuals carry two distinct 
HLA haplotypes; hence in such circumstances, it is difficult to ascertain the 
haplotypic origin of a particular RNA transcript and complicates the analysis 
for association between HLA haplotypes and gene expression. To overcome 
these limitations, Vandiedonck and colleagues [179] used a hybrid microarray 
that includes alternate allele probes to account for known variation in gene 
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sequences. These alternate allele probes were designed based on the 
annotated sequence variation (SNPs) and known segmental duplication in the 
MHC region. The customized MHC array was then applied to the PGF, COX 
and QBL MHC-homozygous LCLs of European-descent and the analysis 
revealed extensive haplotype-related transcriptional differences. Despite the 
impressive efforts to account for the sequence diversity in the MHC region, 
the customized MHC array could not have comprehensively covered all 
possible MHC variation across populations and is limited in revealing novel 
transcripts and splicing isoforms. More importantly, in the study, each MHC 
haplotype was represented by a single cell line; hence there is a possibility 
that the observed transcriptional differences might be attributed to the 
inherent cell lines variation but not the haplotypic variation. 
In this chapter, we adopted the RNA-seq approach to interrogate the 
MHC transcription landscape of Asian CEH (A33-B58-DR3 and A2-B46-DR9) 
using multiple HLA homozygous LCLs for each of the haplotypes. The RNA-
seq approach can allow us to annotate and quantification of all expressed 
transcripts at high level of sensitivity and accuracy [190, 191], accounting for 
the limitations in microarray-based methods. Here, we aim to assess MHC 
haplotype-related expression difference in the Asian CEHs as well as to 














5.2.1 RNA-seq Experimental Design 
RNA-seq datasets were generated from purified total RNA isolated from 
six selected B-LCLs – COX, QBL, B58AL, B58SC, B46BM and B46ZS. Prior 
to the isolation of RNAs, the cell lines were cultured independently in 
duplicates to five passages. The cell lines were then stimulated with 200nm 
PMA and 125nM ionomycin for six hours and harvested at approximate 1 X 
106 cells per ml; the supernatant was then used for the ELISA experiement. 
DMSO were added to unstimulated cell cultures to act as controls. To ensure, 
all the cell lines were sufficiently stimulated and the replicates displayed 
similar profiles, ELISA was performed to quantify the levels of TNF-alpha and 
IL6 proteins in both unstimulated and stimulated cultures. TNF-alpha and IL6 
were previously reported to be up-regulated in B-LCLs [192, 193] and hence 
were selected for the ELISA experiments. The ELISA experiments showed a 
clear increase in production of TNF-alpha and IL6 in stimulated samples 
when compared to the control samples; with an exception for B46ZS cell line 
where there was no or minimal production of IL6 in both stimulated and 
unstimulated culture (Figure 5.1). In addition, consistent proliferation patterns 
of TNF-alpha and IL6 were observed in both replicates across all the cell lines. 
Total RNA were then extracted from the cell pellets collected after stimulation 
and cytoplasmic ribosomal RNA were removed from the DNase-treated total 
RNA. The resulting RNA was then used to prepare RNA-seq libraries 
consisting individually-barcoded RNA fragments and these fragments were 












Figure 5.1 PMA and ionomycin stimulation determined by ELISA. 
Stimulation was performed for six hours and the supernatant was then used 
for the ELISA. DMSO was added in amount equal to the PMA and ionomycin 
into unstimulated cell cultures to act as controls. The ELISA was performed in 






5.2.2 RNA-seq Data Processing, Reads Filtering and Mapping Results 
We had outlined a systematic approach consisting of six phases to 
effectively handle and accurately infer biological implications from the large 
amount data generated by sequencing of the entire human transcriptome 
(Figure 5.2). The RNA-seq analysis in this study would follow closely to the 




















For each sample, we obtained 78,890,079 ± 7,103,330 (mean ± standard 
deviation) 75bp paired-end reads from the RNA-sequencing (Table 5.1). 
Because of the inherent nature of the NGS platforms, there exists a sizeable 
number of sequencing errors and sequence biases in the raw reads [194]. 
Therefore, it is essential to perform quality control to filter out reads of low 
quality to avoid spurious reads alignment resulting in erroneous downstream 
analysis. Here, only reads with 70% of the base positions meet the Phred 
score cuff-off of 20 were retained for the downstream analysis. Phred score is 
an indication for the quality of the reads; a base position with a Phred score of 
20 implies that there is a 1 out of 100 chances that this position is called 
incorrectly [195, 196]. Indeed, the quality of the sequenced reads improved 
after the quality control filtering; the percentage of sequence reads across all 
base positions having a Phred score range of 31-40 significantly increased by 
more than 10% while positions with Phred score of range 1-10 reduced to 
less than 5% after filtering (Figure 5.3) and more than 85% of the original raw 
reads were retained for further analysis (Table 5.1). In terms of the per base 
sequence content of the reads, equal A, T, C and G nucleotide compositions 
were observed at read positions greater than 10 and there was a distinctive 
nucleotide composition variation in the first nine positions of the reads across 
all sequenced samples (Figure 5.4). This distinct nucleotide composition 
variation is due to the use of the random hexamer primers during the 
synthesis of the double-stranded complementary DNA in the library 
preparation step [197] and this bias will be corrected and account for at the 
transcripts abundance quantification step. 
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 Figure 5.3 Paired-end reads base positions score before and after quality 
control filtering (Replicate 1). Red indicates base positions score before 
quality control while blue indicates score after quality control. “|” indicates 
percentage of reads with a Phred score range of 31-40 and “^” indicates 
percentage of reads with a Phred score range of 1-10. 
135 
 
 Figure 5.3 Paired-end reads base positions score before and after quality 
control filtering (Replicate 2). Red indicates base positions score before 
quality control while blue indicates score after quality control. “|” indicates 
percentage of reads with a Phred score range of 31-40 and “^” indicates 






Figure 5.4 Nucleotide composition across all base positions in the 
sequenced reads (Replicate 1). Green indicates composition of “A” nucleotide, 
red indicates composition of “T” nucleotide, blue indicates composition of “C” 




Figure 5.4 Nucleotide composition across all base positions in the 
sequenced reads (Replicate 2). Green indicates composition of “A” nucleotide, 
red indicates composition of “T” nucleotide, blue indicates composition of “C” 













Table 5.1 Quality of raw reads and mapping metrics. 
Replicate 1 
Cell 












B58AL 80,362,945 69,588,080 57,790,683 83.05 45,42,9741 78.61 
B58SC 75,778,660 65,124,362 55,602,319 85.38 41,975,361 75.49 
B46BM 67,751,606 57,936,456 48,472,507 83.66 36,299,920 74.89 
B46ZS 73,156,838 63,331,245 53,152,992 83.93 42,867,424 80.65 
COX 68,449,949 59,742,216 48,925,551 81.89 37,521,696 76.69 
QBL 86,358,133 74,445,714 63,410,379 85.18 48,752,536 76.88 
     
 
 Replicate 2 
Cell 












B58AL 77,249,247 66,485,079 53,928,117 81.11 41,934,497 77.76 
B58SC 86,174,592 74,038,168 59,540,848 80.42 48,681,488 81.76 
B46BM 81,895,555 70,639,184 57,584,590 81.52 44,872,233 77.92 
B46ZS 91,114,107 77,958,277 63,170,151 81.03 50,268,589 79.58 
COX 81,075,411 70,199,584 58,532,731 83.38 43,702,252 74.66 










The QC reads were then mapped to the human reference transcriptome 
(NCBI  gene annotation Build 37.2) as well as to the human reference 
genome (NCBI Build 37.2 reference sequence) using Tophat2 [156]. To 
ensure accurate and high quality reads alignment, post-alignment filtering 
was performed to remove reads that were not mapped in proper pairs – 
paired-end reads that were incorrectly oriented with respect to each other and 
to filter aligned reads with template length that were deviate significantly from 
the expected template length. On a whole, at least 80% of the input reads 
were aligned to the human genome across all cell lines and their replicates, of 
which at least 74% were uniquely mapped to a single location of the genome. 
Direct evaluation of the gene expression level from the mapped reads is 
difficult due to the variation in the number of reads generated from each 
independent sequencing runs and also the sequence biases introduced 
during the library preparation step. To account for these differences, 
normalization procedures are required in order to accurately quantify genes 
expression level. Here, we used the fragments per kilobase of exon per 
million mapped reads (FPKM) implemented in Cufflinks [157] to normalize 
and quantitate the relative gene expression from the assembled reads with 
the NCBI gene annotation Build 37.2 . Subsequently, genes expression (log2-
transformed FPKM values) between the two biological replicates of each cell 
line were compared and evaluated using the square of pearson’s correlation 
coefficient metric (R2). High level of concordance in the genes log2-
transformed FPKM values between the replicates (R2 = 0.96) were observed 
across all the cell lines (Figure 5.5); indicating excellent reproducibility and 







Figure 5.5 Gene expression comparison between cell line replicates. The 
expression of 25549 NCBI annotated loci in the entire genome was 
considered. High correlation in the genome-wide expression profiles between 





5.2.3 Landscape of Transcription in the MHC Region 
The availability of this RNA-seq dataset allowed us to comprehensively 
analyze the transcription landscape of the MHC region in the BLCLs. There 
are 177 genes and pseudogenes annotated in the NCBI gene annotation 
Build 37.2 across the chr6:29.0 – 33.0Mb region and the calculated FPKM 
values of these 177 annotated genes were examined. The distribution of the 
FPKM values was skewed to the left (Figure 5.6A) and the median FPKM 
values range from 1.60 to 2.06 across all the six cell lines with more than 85% 
of the annotated genes having FPKM value less than 50. P-values (>0.05) 
derived from Kolmogorov-Smirnov test indicated there was no difference in 
the FPKM distribution across the cell lines. In addition, the FPKM distribution 
agrees with the RNA-seq dataset derived from the 20 unrelated individuals 
BLCLs in Centre d'Etude du Polymorphisme Humain (CEPH) collection [198] 
showing the reliability of our dataset. The slight aberration in the gene counts 
across FPKM bins observed between the two datasets are likely due to 
inherent cell lines divergence as well as the variation in the handling and 
treatment of the cell lines. Next we will like to determine whether a gene is 
expressed; evaluation of genes with FPKM value greater than zero will 
comprise of genes with FPKM values very close to zero and these are likely 
background noise due the erroneous mapping which cannot be completely 
eradicated. Hence, we set a FPKM value cutoff of 0.01 which is the 5th 
percentile of the genome-wide genes FPKM values across all the cell lines in 
our subsequent analysis. Based on the FPKM value, the level of gene 
expressions were categorized into no expression (FPKM<=0.01), low 
expression (0.01<FPKM<=5), medium expression (5<FPKM<=50) and high 
expression (FPKM>50). The number of genes expressed within the MHC 
region in each cell line agreed well with every other cell lines and the 
proportion of low, medium and high expression genes were also consistent 
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across all the cell lines (Figure 5.6B). Likewise, the proportion on the different 
levels of gene expression in the CEPH dataset is comparable to the MHC 
haplotype cell lines.  
The expression landscape across the MHC region (chr6: 29.0 – 33.0 Mb) 
was explored by examining the gene expression profiles within 100kb bin 
windows and the level of gene expression in each 100kb bin did not varied 
much across different cell lines (Figure 5.6C). Half of the non-expressing 
genes were found at the olfactory cluster (chr6:29.0- 29.60 Mb) which harbor 
numerous olfactory receptor genes while high level of transcription activities 
were observed at the Class II region. A closer look at the gene expression 
profiles based on the functional role revealed that genes coding for proteins 
involved in the antigen processing and presentation were highly expressed as 
compared to those involved in the stress response and regulation (Table 5.2). 
Indeed, the HLA-A, HLA-B and HLA-DRA were one of the most highly 
expressed genes in the MHC region. These suggest genes that are related by 















Figure 5.6 Gene expression profiles within MHC region (A) Distribution of 
FPKM values for genes within the MHC region – chr6:29.0-33.0Mb (B) 
Number of no (FPKM<=0.01), low (0.01<FPKM<=5), medium (5<FPKM<=50) 
and high (FPKM>50) expressing genes in each cell line. (C) Landscape of 






Table 5.2 Gene expression (FPKM) categorized by their functional role.  
Function Genes B58AL B58SC B46BM B46ZS COX QBL 
Antigen 
presentation 
HLA-A 469.31 327.63 439.58 449.52 344.78 254.70 
HLA-E 355.44 275.48 317.32 277.10 319.50 256.64 
HLA-C 236.47 192.29 164.48 163.14 527.82 96.76 
HLA-B 945.18 793.61 541.92 591.96 839.96 494.92 
HLA-DRA 1030.4 1286.1 918.9 856.2 1063.9 1119.8 
HLA-DRB1 250.63 223.30 39.68 38.42 130.13 154.44 
HLA-DQA1 21.74 25.91 2.07 2.54 7.44 6.66 
HLA-DQB1 5.95 5.49 3.21 4.11 2.77 3.23 
HLA-DOB 6.80 6.76 6.04 3.05 7.98 8.94 
HLA-DMB 60.06 23.60 49.96 51.26 35.37 60.22 
HLA-DMA 68.79 39.26 60.19 43.38 64.09 59.76 
Antigen 
processing 
TAP2 55.99 48.14 46.44 53.04 47.72 43.79 
PSMB8 111.04 74.61 148.38 130.73 93.79 103.87 
PSMB9 60.03 40.63 65.45 58.893 43.79 44.32 
TAP1 114.37 128.18 123.79 165.36 114.48 98.66 
Inflammation 
NFKBIL1 8.63 8.20 8.71 6.31 8.03 7.99 
LTA 211.32 185.85 189.19 198.41 210.57 245.51 
TNF 51.71 59.74 51.52 64.80 94.25 66.10 
LTB 8.58 3.19 6.12 14.54 10.90 21.51 
LST1 2.69 3.79 0.83 1.24 1.13 3.78 
NCR3 2.35 1.71 1.62 1.93 2.39 1.86 
AIF1 1.98 13.56 3.13 7.59 2.05 11.29 
Stress 
response 
HSPA1L 1.39 1.90 1.60 1.16 0.87 1.44 
HSPA1A 10.13 17.26 10.46 7.82 5.88 10.76 
HSPA1B 11.61 16.69 13.34 14.24 8.29 8.27 
MICA 3.56 3.47 6.48 8.77 6.49 5.25 
MICB 10.60 8.12 8.78 9.07 7.70 6.70 
Regulatory 
receptors 
AGER 1.21 1.60 1.56 1.04 1.24 0.80 
NOTCH4 0.15 0.18 0.14 0.12 0.10 0.11 
Red = high expression (FPKM>50); blue = medium expression 





Subsequently, the alternative splicing activities in the MHC region were 
assessed. Of the 177 genes analyzed in the region, 51 genes were 
expressed with two or more isoforms and the relative abundance of each of 
the alternatively spliced gene transcripts were examined. The transcript with 
the highest FPKM value was regarded as the major isoform while all other 
isoforms were regarded as minor isoform and the proportion of the major 
isoform FPKM value to the aggregated FPKM value of all expressing 
transcripts of each gene was calculated across all the cell lines (Figure 5.7). 
From this analysis, it was noted that the isoforms were not expressed at 
equivalent level and in fact all the 51 genes had one dominant expressing 
isoform with the exception of TAP2 where both of its isoforms were evenly 
expressed. In addition, there were 15 genes (constituting approximate 30% of 
the genes with multiple isoforms) where one or more cell lines do not share a 



















Figure 5.7 Major isoform proportion relative to all expressing isoforms of a 
gene across the six cell lines. Transcript with the highest FPKM value was 
considered as the major isoform. The “*” indicates that one or more cell lines 
do not shared identical major isoform for a particular gene. Bracket number 





5.2.4 MHC Haplotype-specific Gene Expression 
The access of multiple HLA homozygous cell lines carrying identical MHC 
haplotype that displayed CEHs characteristics has offered a unique 
opportunity to investigate on haplotype-specific expression. In the previous 
chapter, we have showed that independent cell lines carrying identical MHC 
CEHs display high sequence invariant in the MHC region. Therefore it would 
be of interest to examine whether this sequence similarity would correspond 
to similar gene expression profiles among multiple cell lines carrying identical 
MHC haplotype (B58AL and B5SC – A33-B58-DR3; B46BM and B46ZS – A2-
B46-DR9).  To do this, principal component analysis (PCA) was applied to the 
expression data of the 177 MHC region genes represented by their FPKM 
values. The PCA results showed haplotype-specific clustering while surprising 
the QBL cell line had highly similar expression profile with the cell lines 
carrying A2-B46-DR9 haplotype (Figure 5.8). This data suggests that cell 
lines carrying identical Asian MHC CEH have probable correlation in their 
gene expression profile at the MHC region. Next, quantitative differences in 
gene expression levels between the MHC haplotypes were assessed by the 
grouping cell lines with identical MHC CEHs. Pairwise fold-change 
comparison of every possible MHC haplotype combinations was performed to 
provide a regional view of the transcription differences between the MHC 
haplotypes (Figure 5.9). Heighten transcriptional variation between 
haplotypes were found to be localized to regions proximate to the HLA genes 
as well as the genes cluster involved in inflammation, highlighting the 














Figure 5.8 PCA analysis based on the relative abundance (expression) of 
177 MHC region genes. Red indicates cell lines carrying A33-B58-DR3 MHC 
haplotype; blue indicates cell lines carrying A2-B46-DR9 MHC haplotype and 














Figure 5.9 Pairwise comparisons of A33-B58-DR3 vs A1-B8-DR3 (COX),  
A33-B58-DR3 vs A26-B18-DR3  (QBL), A33-B58-DR3 vs A2-B46-DR9, A2-
B46-DR9 vs A1-B8-DR3, A2-B46-DR9 vs A26-B18-DR3 and A1-B8-DR3 vs 
A26-B18-DR3. Fold change (FC) derived from the log2 ratio of gene FPKM 
values between two haplotypes. Blue circle indicates higher expression in the 






































UBD  0.02 NS  1.70 ** -0.80 *  2.50 **  0.83 *  1.68 ** 
GABBR1 -2.61 **  1.50 NS -1.47 NS  2.97 NS -1.14 NS  4.11 ** 
ZFP57 -9.84 **  0.00 NS -7.93 **  7.93 ** -1.91 **  9.84 ** 
HLA-H  1.00 **  2.23 **  1.43 **  0.80 NS  0.26 NS  0.54 NS 
HLA-A  0.21 NS  0.65 * -0.13 NS  0.78 **  0.34 NS  0.44 NS 
HLA-L  0.75 NS  1.10 **  2.11 ** -1.01 NS -1.36 **  0.35 NS 
DDR1  0.59 NS  0.52 NS  1.44 ** -0.92 * -0.85 NS -0.07 NS 
DPCR1 -0.37 NS  0.06 NS  1.59 ** -1.54 * -1.96 **  0.42 NS 
HCG22 -0.26 NS -0.73 NS  1.47 ** -2.19 ** -1.73 ** -0.46 NS 
POU5F1 -1.89 *  0.98 NS -1.60 *  2.59 ** -0.28 NS  2.87 ** 
PSORS1C3  1.79 NS  1.79 NS -4.32 NS  6.10 **  6.10 **  0.00 NS 
HLA-C -1.29 **  1.15 **  0.42 NS  0.73 ** -1.72 **  2.45 ** 
HLA-B  0.05 NS  0.82 **  0.64 **  0.17 NS -0.59 NS  0.70 * 
MICA -0.82 NS -0.51 NS -1.14 **  0.63 NS  0.32 NS  0.30 NS 
TNF -0.73 ** -0.22 NS -0.03 NS -0.19 NS -0.70 *  0.51 NS 
LTB -0.92 NS -1.90 ** -0.74 NS -1.16 ** -0.18 NS -0.98 NS 
AIF1  2.09 ** -0.37 NS  0.59 NS -0.95 NS  1.51 NS -2.46 ** 
HSPA1A  1.25 **  0.38 NS  0.62 NS -0.24 NS  0.63 NS -0.87 NS 
C6orf48 -0.16 NS  0.21 NS  1.15 ** -0.93 ** -1.31 **  0.38 NS 
NEU1  0.25 NS  0.36 NS  0.64 ** -0.27 NS -0.39 NS  0.11 NS 
HLA-DRB5  8.33 **  6.68 NS  2.51 **  4.18 NS  5.82 ** -1.64 NS 
HLA-DRB1  0.90 **  0.65 *  2.59 ** -1.95 ** -1.70 ** -0.25 NS 
HLA-DQA1  1.67 **  1.83 **  3.40 ** -1.57 ** -1.73 **  0.16 NS 
HLA-DQA2  0.88 NS  0.90 NS -0.96 **  1.87 **  1.84 **  0.03 NS 
HLA-DQB2  0.66 NS  0.74 NS  1.31 ** -0.57 NS -0.65 NS  0.09 NS 
HLA-DOA  0.24 NS -0.12 NS  0.93 ** -1.06 ** -0.69 NS -0.36 NS 
Genes showing significant differentially expressed in one or more haplotype-
pairs comparison after Benjamini-Hochberg adjustment. “NS” denotes not 
significant haplotype-pair; “**” denotes haplotype-pair with adjusted P-value 
<0.05; “*” denotes haplotype-pair with adjusted P-value <0.1. COX cell line 
carries the A1-B8-DR3 haplotype while QBL cell line carries the A26-B18-





To detect differentially expressed genes, the method implemented in 
Cuffdiff 2 was employed [157]. Overall, 26 genes were significantly 
differentially expressed (adjusted P-value<0.05) in at least one pair of 
haplotype comparison (Table 5.3). A number of these genes that are related 
to the antigen presentation (HLA-A, HLA-C, HLA-B, HLA-DRB1, HLA-DQA1, 
HLA-DQA2, HLA-DQB2) as well as the inflammatory genes (TNF, LTB, AIF1). 
As the variation in the gene expression levels could be due to individual cell 
line differences rather than haplotype-specific differences, we selected 12 
genes that were found to be significantly differentially expressed in three or 
more haplotype-pairs comparison and inspect on the expression levels of 
these genes in each of the six individual cell lines. Indeed, with the exception 
of ZFP57, equivalent expression levels were observed in cell lines sharing 
identical MHC haplotype for the 11 selected genes (Figure 5.10). These 
provide strong evidence for the influence of haplotypic sequence variation on 























































































































































































































































































































5.2.5 ZFP57 Expression 
The RNA-seq data allows us to verify the expression of ZFP57 as well as 
assesses the possible isoforms expressed in the cell lines. Indeed, the RNA-
seq data correlates with the RT-qPCR experimental results where expression 
of ZFP57 was found in the B46BM and COX cell lines (Figure 5.10). Next, we 
also examined the possible expressing isoforms by plotting the sashimi plots 
which displayed the raw reads coverage mapped to the exons and splicing 
junctions (Figure 5.11). Currently there are two known ZFP57 isoforms which 
is differed by the extension of the 5’ UTR. From the RNA-seq reads, it 
appears both isoforms are expressed in the cell lines. In addition, there is 
indication for the expression of a third shorter novel isoform which lack of the 
first exon of the previous isoforms. However this observation could be an 
artifact resulted from erroneous reads mapping and therefore more 
quantitative analysis and verification by experimental approaches are needed 



















Figure 5.11 Sashimi plots for RNA-Seq analysis of ZFP57 expression. Raw 
read densities mapped along the exons and splicing junctions of ZFP57 in 
B46BM and COX cell lines. Spicing junctions are represented by the 
connecting lines and the number below each line indicates the number of 
reads spanning across each splicing junction. Below the sashimi plots are the 
known ZFP57 isoforms from the NCBI gene annotation Build 37.2 and 







In this chapter, using RNA-seq technology on multiple HLA homozygous 
LCLs sharing identical HLA haplotype, we provided a comprehensive 
description on the transcriptional landscape in the MHC region (chr6:29.0 – 
33.0Mb) for four common HLA haplotype (two with Asian ancestry – A33-
B358-DR3 and A2-B46-DR9; two with European ancestry – A1-B8-DR3 and 
A26-B18-DR3). We observed elevated expression of the HLA class I / class II 
genes and genes related by their functions were expressed at equivalent 
levels. In addition, differences in gene expression as well as in alternate 
splicing events were influenced by the underlying MHC haplotypic structure. 
The transcription activities of 26 genes were found to be affected by the MHC 
haplotype diversity. This implies that underlying MHC haplotypic structure 



































6.1 Significance of the MHC Recombination Analysis in this Study 
Current in silico approaches using of population genetics data is relatively 
successful in estimating the location of recombination sites on a genome-wide 
basis [199] which are showed to have good correlation with predigree-derived 
recombination maps and with known recombination sites. Most of these 
approaches are based on a population genetic model that does not account 
for natural selection, random mutation, human migration and variation of the 
effective population size [200]. Though it has proved to be robust with 
reasonable departure from those conditions, cautious has to be exercised 
when applying the model to infer recombination sites in the human MHC 
region given that this region is subjected to strong selection forces. The 
human MHC region is unique as it is characterized by diverse HLA haplotypic 
variation and structure. In silico approaches that used pooled global 
population data is unable to effectively account for the contribution of HLA 
allelic haplotypes towards recombination. The admixture of diverse HLA 
haplotypes complicates the inference process and obscures potential 
recombination sites.  To address the problem, in this work, EHH plots using 
phased HLA haplotypes derived from CHSG were employed to identify MHC-
residing recombination sites. This method was demonstrated to be an 
effective tool at locating recombination sites in the extended MHC region. The 
69 putative recombination sites identified in this study correlate well with 
recombination segments determined by sperm typing [47] as well as with the 
majority of HapMap predicted sites [160]. We also uncovered an additional 37 
sites that are not found in any of the previous studies. A review of recent 
reports [201, 202] based on European pedigree information, ascertains that 
our approach is far more sensitive at locating recombination events (69 sites 
vs 5 sites) within MHC and provides superior resolution (average 4.27kb vs 
100kb intervals).   
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Earlier studies from Walsh et al [50] and Ahmad et al [203] have 
characterized the LD patterns of the Caucasian population. Though these 
studies highlighted the extent of LD within the MHC region, the resultant LD 
maps were limited in scope due to the relative small amount of polymorphic 
markers used to derive them and could not be used to infer recombination 
sites. A more recent study created a comprehensive haplotype map by 
investigating the LD between the SNPs and the HLA alleles across the 
extended MHC region (7.5Mb) in four populations [163]. This study effectively 
demonstrated that the extent of LD along the chromosome is dependent on 
the underlying HLA allelic haplotype and provided a panoramic view of the 
MHC genomic architecture. In comparison, our study provides a more detail 
and precise description on the variation of LD structure and breakages in 
distinctive HLA haplotypes localized to the HLA class I and class II gene 
regions where the LD breakpoints are interpreted as probable recombination 
sites. 
 
6.2 Population-specific Recombination  
The International HapMap Project reported over 33,000 genome-wide 
recombination sites derived from a pooled population comprising of CEU, YRI 
and an Asian population (Han Chinese, CHB and Japanese, JPT) [137, 204]. 
These HapMap recombination sites were classified only when two out of the 
three populations showed signal of recombination events, and hence, 
HapMap inferred recombination sites are commonly found across 
populations, not population-specific. Indeed, there is no extensive study to 
examine recombination variation across populations within MHC region. In 
the study by de Bakker et al [52], the recombination rates were separately 
estimated from individuals of a distinct population and coalesced the rates 
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from four different populations into a single estimate for the MHC region, but 
did not delved further to evaluate the differences in recombination rates 
between populations. A subsequent study did a recombination rates 
correlation analysis on the LD-maps generated from three populations and 
found population recombination variation at the whole genome level [205]. 
However this study did not investigate on how the differences of the HLA 
haplotypes pool in each distinct population influence and affect the 
recombination variation in the MHC region. To provide a clearer insight into 
the population-specific recombination profile and the effect of underlying HLA 
haplotype on recombination variations, we applied the EHH approach coupled 
with the HLA information of the CHSG, CEU and YRI population. Our study 
shows low number of recombination sites overlap in multiple populations; in 
fact, > 50% of the identified recombination sites is specific to a single 
population. Recombination activities bring about the breakdown of LD and 
have a direct effect on the genome haplotype diversity [44]. The findings of 
vast number of unique recombination sites in a distinct population suggest 
that these population-specific sites could have a major role in the 
diversification of haplotypes in the MHC region. In contrast, in other parts of 
the human genome, the sites of LD decay are generally common across 
populations; resulting in extensive haplotype sharing among different 
populations [148, 161]. Given that the genomic region of the MHC can be 
influenced by a variety of evolutionary mechanisms such as genetic drift, 
demography and natural selection, the distribution of population 
recombination sites in the MHC region may not be a good refection on the 
recombination distribution elsewhere in the human genome. 
Balancing selection through pathogen mediated selection are proposed to 
explain for the immense number of HLA alleles and haplotypes [206]. These 
selection forces favor new assortment of HLA allelic combinations across 
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populations and lead to an increase in population frequency of these HLA 
combinations [15]. These mechanisms result in the occurrence of a given 
allele in two or more different HLA haplotype backgrounds. In this study, the 
A*02:01 allele is independently found in different HLA haplotype background 
in multiple populations and their recombination profiles varies across 
populations; indicating the combinatorial effects of underlying HLA haplotype 
and population background on recombination. On the whole, our data shows 
the significant role of HLA haplotypes on the patterns and occurrence of 
recombination events in the MHC region; and the discovery of unique 
recombination sites are possible only through single population analysis. 
  
6.3 Evolutionary Conserved Recombination Sites 
Previous section highlighted the differences of recombination sites between 
population groups; however, few sites are observed to be shared between 
populations (Table 3.3) and these are also of interest as this means that they 
are evolutionarily highly conserved and could therefore be of great 
importance. Though explanation for the mechanism behind the occurrence of 
these conserved recombination sites is not well-defined, one can study the 
recombination pathways to derive possible hypotheses. Initiation of 
recombination at a particular site starts when histone methyltransferase such 
as PR domain-containing 9 (Prdm9), locally acts and opens up the chromatin. 
This allows the topoisomerase sporulation-specific 11 (SPO11) to introduce 
double-strand breaks (DSBs) on the chromatid and the DSBs are then 
repaired through the process of homologous recombination resulting in cross-
over or gene conversion events [207]. Therefore it could be possible that the 
local chromatin state at the conserved recombination sites is highly favorable 
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for the recruitment of recombination-initiation machinery.  Another probable 
hypothesis can be derived from the need to balance the two divergent 
mechanisms during meiosis where recombination is essential for proper 
chromosome separation but it also has to be controlled to minimize the 
breakage of important gene clusters and to maintain genome stability [44]. 
The occurrence of conserved recombination sites could suggest 
recombination activities at these genomic sites are conducive for the proper 
repair of DSBs; as such, would not disrupt the favorable linkage of gene 
clusters and would have little or no deleterious effect on the genome stability. 
 
6.4 Sequencing MHC CEHs and Intra-haplotypic Variations  
In this study, the presence of Singaporean Chinese CEHs in A33-B58-
DR3 and A2-B46-DR9 HLA haplotypes were identified through SNP 
genotyping as well as deep sequencing of the MHC region (28.5 to 33.5 Mb). 
We have assembled at least 90% of the MHC sequence representative of the 
A33-B58-DR3 and A2-B46-DR9 haplotypes; and discovered that the 
sequences of these haplotypes are largely conserved from HLA-F to HLA-
DQA2 loci covering at least 3Mb of the MHC genomic region, proving the 
CEH nature of these haplotypes. The assembly of these common Singapore 
Chinese MHC sequences could act as an important framework for future 
disease studies on populations enriched with these haplotypes, which include 
Asian populations from Southern China and Taiwan [173, 174, 208]. 
Genome-wide association studies have identified more than 100 diseases 
that are implicated by the variants or genes within the MHC region [7]. Often, 
such genetic associations are not due to single specific variants, but by the 
underlying MHC haplotype structure marked by extensive LD [13]. These 
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issues have complicated the identification of disease-causing variants or 
genes within the MHC region, especially in common CEHs, where extreme 
LD is often found. By deep sequencing of multiple individuals homozygous for 
the same haplotype, we were able to circumvent the assignment of haplotype 
chromosome and perform intra-haplotypic CEH comparison at the nucleotide 
level to determine the extent of variation within the conserved boundaries of 
each CEH. In total, more than 200 haplotype-specific SNVs were uncovered 
residing in each haplotype, up to a third of which are not annotated in any 
public archives for genetic polymorphism. In contrast, the use of the common 
SNP genotyping platform to interrogate the CEHs was unable to reveal the 
polymorphisms embedded within the conserved region. The ability to reveal 
variants that is enriched at the haplotype level but not at the population level 
allows fine discrimination within members containing the same CEH. This 
may allow us to better predict case-control status among individuals sharing 
the same risk-associated CEH, and also to define risk-associated variants 
that may be enhanced within a particular CEH. 
The intra-haplotypic variations revealed in our study suggests that the 
pattern of variations in each CEH is unique. For example, a hyper-variable 
region was observed around the HLA-A region on the A33-B58-DR3 but not 
on A2-B46-DR9. Given that each MHC CEH has a distinct underlying HLA 
background and evolutionary history, and has been subjected to different 
environmental influences, such non-homogeneous variation distribution may 
be expected. The increase in variation around HLA-A in A33-B58-DR3 
despite the apparent lack of recombination in this haplotype hints at the 
presence of non-random mutation in the region. The existence of non-random 
mutation rates across the genome has been recognized in organisms as 
diverse as bacteria and humans relatively recently, and there are still many 
164 
 
unknowns regarding the biochemical mechanisms behind such phenomena 
[209-211]. It is tempting to speculate that specific genetic characteristics of 
HLA-A may increase its mutation rate, contributing to the increased global 
diversity observed at the locus in a manner independent but complementary 
to balancing selection. In fact, the occurrence of these intra-haplotypic 
variants where 99% of the A33-B58-DR3 and  23% of the A2-B46-DR9 
variants exist in the heterozygote form can be well explained by an alternate 
model on MHC evolution called Associative Balancing Complex (ABC) [79]. 
This model states that recessive detrimental mutations are built up by the 
Muller’s ratchet effect and are sheltered by the surrounding MHC genes 
through LD. Moreover, these mutations exist in the heterozygote forms and 
as such natural selection is not effective to select against these mutations. 
This leads to negative epistasis and the reduction of recombination events in 
the MHC. The ABC evolution model therefore accounts for the high number of 
heterozygous intra-haplotypic variants in the MHC CEHs and may provide a 
valid explanation for why numerous diseases are associated to MHC CEHs.  
The identified intra- and inter-haplotypic variants in this work may be 
helpful in offering important clinical links to diseases. MHC-resident variants 
within the CEHs, apart from the HLA genes, have independent associations 
with diseases, even in autoimmune-related disorders such as systemic lupus 
erythematosus, Behcet’s disease, graft-versus-host disease and rheumatoid 
arthritis [212-216].  These variants may exert cis-regulatory effects on the 
nearby genes and affect the expression of the target genes commonly known 
as cis-expression quantitative trait loci (cis-eQTLs). Recent studies have 
suggested that the MHC region is a prominent area for such cis-eQTL 
associations [133, 217, 218], and in our study, we also show that one of the 
A2-B46-DR9 intra-haplotypic variant regulates the expression of the ZFP57 
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gene. The presence of such cis-eQTLs provides a possible mechanistic 
theory for the outstanding number of MHC disease associations yet to be 
explained, particularly the contribution of non-coding variants to disease 
phenotypes. In this work, up to 99% of the intra-haplotypic variations are 
located within the non-coding region; these variants can be incorporated into 
a reference panel to infer the effects of non-coding variants on diseases. 
The numerous associations of MHC CEHs with various diseases signal a 
need to dissect CEHs to identify the true disease-causing variants among the 
large pool of benign variants in LD within the haplotype. Hence, it is essential 
to characterize the extent of variation within the MHC CEHs. The advent of 
next-generation sequencing technology offers an attractive option to assess 
such haplotypic variation. However, the short reads generated by NGS 
platforms are not well suited to accurately map the MHC region given its 
extreme sequence and structural variations. More importantly, it is difficult to 
resolve the phase of the haplotype from the short reads mapping. As seen in 
this study, the use of HLA homozygous cell lines avoids the need for phasing 
and improves the accuracy of the reads mapping. Third generation 
sequencing technologies with the ability to sequence reads of length greater 
than 1000bp [219, 220] have the potential to both phase and accurately map 
complex region such within the MHC and will eventually allow large scale 







6.5 Origin and Age of Conserved Extended Haplotype (CEH) 
The MHC CEHs can span over several megabases contain numerous 
genes that are fundamental for human immune functions. The mechanism 
behind the maintenance of such extensive LD in this important and highly 
variable region of the human genome is unclear.  There are two plausible 
explanations for the generation of MHC CEHs. The first is that these long 
sweeps of conserved sequence haplotypes may have been driven to high 
frequency by positive selection over a relatively short period of time and have 
yet to be disrupted by recombination events [10, 144]. A single gene or a 
combination of genes within the conserved stretch would be adequate to drive 
the haplotype expansion in the population. Another possibility is that given the 
almost non-existent of recombination events on haplotypes carrying a specific 
HLA allelic combination, these extensive conserved segments are exposed to 
allele-specific recombination suppression preventing haplotype breakdown 
[203]. The age of the A1-B8-DR3 haplotype has been estimated to be about 
23,500 years [21]. The relative young age of the A1-B8-DR3 suggests that 
the extensive LD observed between the HLA alleles is more likely due to 
recent expansion and that recombination forces have yet to act on this 
haplotype. Assuming that the human mutation rate per nucleotide per 
generation is 1.1X10-8 [154] and a given generation is 20 years, the age of the 
Asian A33-B58-DR3 and A2-B46-DR9 works out to be about 21,460 and 
26,500 years respectively. These values are compatible with the age of the 
A1-B8-DR3 haplotype lending support to the theory that these MHC CEHs 
are likely to be resulted from recent expansion. In addition, it has been 
suggested that the expansion of the CEHs is possibly because of a single 
HLA allele under strong positive selection rather than epistatic selection of a 
specific HLA allelic combination [10]. This study reports the occurrence of 
167 
 
sequence similarity at the HLA-DRB region between two common CEHs 
(A33-B58-DR3 and A1-B8-DR3) which belong to different ethnic backgrounds 
but were both driven to high frequency in their respective populations. It is 
conceivable that this ancestral DR3 segment was introduced into different 
MHC haplotype background whereby the selection for this segment drove the 
expansion of these MHC haplotypes.   
Where is the origin of this DR3 ancestral segment? Given that the A33-
B58-DR3 and A1-B8-DR haplotypes are found in populations that are 
geographically distant to each other, it is unlikely that the DR3 segment is 
derived from either of the two haplotypes. It is more likely that this segment 
could originate from another population group and diverge into the European 
and Chinese population. The study of the human migration pattern might able 
to provide insight to this hypothesis. Based on the Out of Africa theory, 
human first migrated out of Africa into Middle Asia then spread to South Asia 
by 50,000 years ago, and from South Asia human slowly spread to China, 
South East Asia and then finally reached Europe by 40,000 years ago [221, 
222]. Literature search on the MHC haplotype distribution has revealed an 
enrichment of DR3 in the modern South Asian population (A24-B8-DR3 - 
4.8% & A26-B8-DR3 - 6.2%) [170], hence it is plausible that the DR3 segment 
could origin from the South Asian population and then independently expands 
in the European and Chinese population through human migration. To 
validate this model, further work has to be conducted to ensure DR3 
sequence similarity can be found between the South Asian DR3 and the 
Chinese/European DR3 segment and preferably supported by the age of the 




6.6 Influence of Haplotype-defined Nucleotide Sequence Variation on 
MHC Gene Regulation 
There are many instances where the underlying HLA haplotype rather 
than genotype of a specific locus plays a significant role in disease 
susceptibility [13, 223, 224]. In this thesis, we have unambiguously identified 
haplotype-specific sequence variations. Though the knowledge of these 
variations is important for the explanation of the occurrence of the disease, it 
could not have revealed the functional mechanisms that lead to disease 
progression. Therefore, the ability to map the transcriptomic landscape of the 
MHC region at haplotypic resolution is an important step in understanding the 
molecular basis for a number of MHC associations to diseases.  In this study, 
the MHC transcriptome profiles of multiple HLA homozygous B-LCLs with 
identical Singaporean Chinese HLA haplotype were examined using RNA-seq. 
This approach not only averts the confounding effect in the evaluation of 
diploid genome but will also account for transcription variability between cell 
lines. Overall, our study has revealed that the expressions of 26 genes are 
attributed to haplotypic effects. In comparison, the report by Vandiedonck et 
al [179] which was based on the analysis of three common European MHC 
haplotypes identified 96 genes whose expression levels are associated to 
haplotypic differences. There are two likely reasons for this discrepancy. The 
first is the difference in the MHC haplotypes used in context between the two 
studies. Secondly, in the work by Vandiedonck et al, each MHC haplotype 
was represented by only a single cell line; hence some of the transcription 
differences reported could be due to individual cell lines variations rather than 
haplotype-related transcriptional differences. In contrast, our analysis involved 
two independent cell lines carrying identical MHC haplotype and we showed 
that haplotype-identical cell lines have equivalent expression in 25 out 26 
genes.  This provides strong evidence that the differential gene expression 
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observed is indeed due to haplotypic effects and dismisses the notion of 
individual cell lines variations. Nevertheless, 15/26 differentially expressed 
genes identified in this thesis overlapped with the genes listed in 
Vandiedonck’s work. This suggests the MHC transcriptional landscape is 
likely to vary in a context-specific manner; dependent on the relevant 
haplotype of interest, the cell types and conditions applied. Together, the 
identification of genes whose expression levels are implicated by haplotypic 
differences allow us to shortlist candidate genes to consider for diseases 
linked to the haplotype in context.    
Haplotype-related transcriptional differences signify the possible effect of 
haplotype-defined nucleotide sequence variations on MHC gene regulation. 
Haplotype-specific sequence variations in cis–acting regulatory promoter 
elements or even distal trans-acting regulatory elements could affect DNA 
methylation or chromatin accessibility and hence are critical to the regulation 
of gene expression. Indeed, sequence variations in the enhancer and the 
interferon-stimulated response element in the MHC class I promoter bring 
about differential promoter activation among various MHC class I loci [120, 
225]. Currently, much of the MHC epigenetic studies are directed at the 
regulation of transcription initiation. The complex interplay between cris-
/trans- regulatory elements and the epigenetic mechanisms that modulate the 
expression of MHC class I and class II genes are well established  [118, 226, 
227].  However, the effect of sequence diversity, in particular sequence 
variants defined by the MHC haplotypic structure, on epigenetic modifications 
is not well understood. Haplotype-specific sequence diversity can influence 
the entire transcription as well as translation process and also defines the 
packing of the chromatin that coordinates gene expression at local and global 
level. Hence, the establishment and mapping chromatin modification at 
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haplotypic resolution could well provide the mechanistic explanation on how 
transcription is modulated by underlying sequence variation. The ability to 
connect MHC sequence variation, chromatin modification and the subsequent 
transcription process has enormous potential to provide insight into the 
functional basis for many complex diseases linked to the MHC region.  
6.7 Future Directions 
In this thesis, we found that certain individuals showed expression of 
ZFP57, a Kruppel-associated box (KRAB) containing zinc-finger protein, in 
the B-LCLs; dependent on the nucleotide sequence configuration at multiple 
positions proximate to the gene. These positions signify possible regulatory 
sites for the transcription of ZFP57; therefore further work is required to 
ascertain which of these site(s) truly regulate the expression of the gene.  
Approach such as cloning the genomic segments bearing these sites into an 
expression vector and transfect them into a non-expressing ZFP57 
mammalian cell can be used to identify the possible regulatory region. This 
identification of ZFP57 regulatory region(s) can facilitate the finding of the 
transcription factors or other co-factors that may involve in the modulation of 
the ZFP57 transcription. In embryonic stem (ES) cells, signal transducer and 
activator of transcription 3 (STAT3) and octamer-binding transcription factor -
3/4 (Oct-3/4) are the transcription activators for ZFP57 [228], it would be of 
interest to examine whether the same transcription factors or other novel 
factors are utilized to regulate the transcription ZFP57 in adult cell lines.  
To date, ZFP57 is involved in the maintenance of DNA methylation 
whereby ZFP57 acts as an anchor for the binding of KAP1 and the 
recruitment of other epigenetic regulators at imprinting control regions in the 
ES cells [229]. However, functional significance of the expression of ZFP57 
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and its role in the adult cells is not known. The KRAB-ZNF family genes have 
various functions such as cell-cycle regulation [230], specification of meiotic 
recombination hotspots [231] and more importantly some of the KRAB-ZNF 
genes exhibit tumor suppression properties [230]. In addition, ZFP57’s co-
factor KAP1 is found to be associated with tumor developments in several 
studies [232-234]. Hence further work is needed to investigate on the role of 
ZFP57 in epigenetic regulation in the context of cancers or infection.  
The A2-B46-DR9 and A33-B58-DR3 HLA haplotypes are implicated in 
multiple diseases. Most notably, several studies have reported the 
association of these haplotypes with nasopharyngeal carcinoma [235-237] 
and a recent GWAS study has identified 3 new susceptibility loci with 
extremely strong statistical significance within the MHC region [82]; but the 
exact location of the disease causative variant/element is yet to be 
determined. The findings of A2-B46-DR9 and A33-B58-DR3 haplotype-
specific sequence variations in this study, in particular the novel variants not 
reported in any prior studies, offer an excellent opportunity to revisit these 
association studies. These haplotype-specific variations might be able to 
distinguish disease-affected haplotype carriers from unaffected haplotype 
carriers and eventually facilitate the mapping of the disease causative 
variant/element. 
 
Increasingly in recent years, it is apparent that a significant fraction of the 
human genome expresses non-coding RNAs (ncRNAs) and some these 
ncRNAs are crucial for normal development and physiology [238]. Hence, it is 
not surprising that many of them are implicated in numerous diseases. Many 
studies have showed that the dysregulation of these ncRNAs contribute to the 
development and progression of many human conditions particularly in 
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cancers [239-241]. It would be of interested to investigate the presence of 
ncRNAs in the MHC region and more significantly to examine whether the 
underlying haplotype structure would influence the expression of ncRNAs. 
Through de novo analysis, the RNA-seq data used in this study can be 
employed to inspect the expression of the ncRNAs in the Singaporean 
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